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It is currently unclear how mammary epithelial cells organize in acinar structures and which 
genetic signals are involved in this process, even though distinct patterns of gene expression are 
considered the base to orchestrate fine tuned cellular decisions. MEF2 transcription factors are 
important players driving and controlling morphogenetic and differentiation processes in several 
districts of the body and their activity is highly and tightly regulated by class IIa HDACs. 
Despite described their central role during development, MEF2 factors and class IIa HDACs 
involvement in epithelial morphogenesis is still not characterized. Here, using 3D culture of 
human mammary MCF-10A acini as a model of study, we investigated the effect of the MEF2-
HDAC pathway to elucidate its contribution in the epithelial side and its alteration by HER2, a 
known oncogene in breast cancer. We showed that MEF2-dependent transcription is up-
regulated during acini formation and is coupled to a down-regulation of HDAC7, the most 
expressed class IIa HDAC in our model, which occurs independently from changes in mRNA 
levels, proteasome or autophagy mediated degradation. Pertubation of MEF2 activity, using 
shRNA lentiviral vectors or overexpressing a MEF2 or HDAC7 inducible form, affects cell 
proliferation controlling the expression of the cyclin-dependent kinase inhibitor 1A (CDKN1A). 
Only in proliferating cells HDAC7 can bind the first intron of the CDKN1A gene, a region 
characterized by epigenetic markers of active promoters/enhancers. In cells overexpressing the 
HER2 oncogene 3D epithelial morphogenesis is altered, HDAC7 is continuously expressed and 
MEF2-dependent transcription is repressed. Importantly reactivation of MEF2 transcription in 
these cells, blocking HER2 activity or enhancing MEF2 function, reverted the proliferative 
defect and re-established normal acini morphogenesis. 
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The Myocyte Enhancer Factor 2 (MEF2) family of transcription factors. 
 
Structure of the MEF2 family members. 
 
MEF2s, Myocyte Enhancer Factor 2, belong to the MADS (MCM1, agamous, deficiens, SRF) 
family of transcription factors (TFs). Saccharomyces cerevisiae, Drosophila, and C. elegans 
possess a single MEF2 gene, while in vertebrates the family of MEF2s includes four 
transcriptional activators: MEF2A, -B, -C, and –D, which are located on different chromosomes. 
Members of this family share a highly conserved 57 amino acid (AA) region, known as MADS-
box domain, with the other MADS-box proteins, located at the extreme amino-terminal region 
and an adjacent 29 amino acid (AA) motif, termed MEF2 domain, exclusive to the MEF2 
factors. Together these two domains mediate the homo- and heterodimerization of MEF2 
proteins, the binding to a conserved A-T rich DNA consensus sequence, YTA(A/T)4TAR, and 
the interactions with transcriptional co-factors and co-regulators (Black and Olson, 
1998)(Timothy A. McKinsey et al., 2002). The carboxyl- terminal region of MEF2 proteins is 
more divergent and variable between individual MEF2 family members. It contains a potent 
transcriptional activation domain (TAD) and a nuclear localization signal (NLS) and it is subject 
to complex patterns of alternative splicing (Figure 1)(J. F. Martin et al., 1994)(Potthoff and 
Olson, 2007). Members of the MEF2 family are relatively weak transcriptional activators and 
they cooperate and associate with other transcription factors to control and drive the expression 
of specific set of downstream target genes involved in different cellular programs.  
 
Tissue and cell type distribution of MEF2 proteins. 
 
In vertebrates MEF2 factors show distinct, but overlapping, expression patterns during the 
process of embryogenesis and in adult tissues (Potthoff and Olson, 2007). MEF2A, -B, and -D 
proteins are ubiquitously expressed, whereas MEF2C shows mainly expression in skeletal 
muscle, heart and brain. MEF2 factors have a very important role and function in the 
differentiation processes of several cell types, including muscle (cardiac, smooth and skeletal), 
neurons, chondrocytes and lymphocytes. In these tissues their expression is concomitant with the 
activation of differentiation programs, which are highly controlled by different regulatory 
mechanisms. Members of MEF2 family interact and associate with a variety of transcriptional 
co-factors that modulate MEF2 activity in a positive or negative manner during the tissue 
development (Arnold et al., 2007)(Lu et al., 2000)(Verzi et al., 2007). 
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Figure 1: Schematic diagram of MEF2 structure and protein interaction domains. 
A schematic representation of the MEF2 structure, including binding sites for key repressors 
(HDACs) and transcription activators (CBP/p300). MEF2 proteins are comprised of three 
domains: the N-terminal MADS-box and MEF2 domains, and the C-terminal transactivation 
domain. The N-terminal domains are responsible for DNA binding, dimerization and co-factors 
interactions, whereas the C-terminal domain contains the transactivation domain (adapted from 
Timothy A. McKinsey et al., 2002). 
 
 
Function and regulation of MEF2 activity.  
 
The transcription factors of MEF2 family act as transcriptional activators or repressors through 
the direct binding to the promoters or enhancers of a variety of specific genes, thus mediating 
and controlling multiple and different cellular functions. In this way MEF2 proteins cooperate 
through protein-protein interactions with other transcriptional factors to control specific sets of 
target genes. MEF2 expression and activity is under a tight and complex regulation that occurs 
through different and complex transcriptional, translational and post-translational mechanisms. 
This complexity provides the possibility to regulate and govern the function of the family 
members at multiple time points during cell differentiation and growth.  
 
Regulation of MEF2 activity by post-translational modifications. 
 
Many post-translational modifications (PTMs) including phosphorylation, sumoylation, 
methylation, and acetylation, can influence and govern positively or negatively activity of MEF2 
factors, enhancing or suppressing their activities during different cellular programs. 
Phosphorylation plays an important role in the regulation and activation of MEF2 family 
members. MEF2 proteins contain a single conserved phosphorylation serine residue in the 
MADS MEF2 Transactivation domainNH2 COOH
Dimerization
DNA binding
HDACs CPB/p300
                                                                                                                                                      Introduction 
6 
 
MADS-box domain (Molkentin et al., 1996) and multiple phosphorylation sites in the 
transactivation domain (Cox et al., 2003). The phosphorylation in the MADS-domain induces 
conformational changes, which lead to the activation of MEF2 factors. Kinases involved include 
members of the mitogen-activated protein (MAP) kinase family. The MAPKs, such as p38, JNK 
and ERK5 can enhance the transcriptional activity of MEF2s in a variety of cell types, by 
phosphorylating MEF2s in the transactivation domain without affecting DNA binding (H G 
Kasler et al., 2000)(Miska et al., 2001). Conversely the cyclin-dependent kinase 5 (Cdk5) 
phosphorylates MEF2s in the transactivation domain (Ser444 in MEF2D) and inhibits MEF2 
activity (Gong et al., 2003)(Gregoire et al., 2006). During muscle differentiation, 
phosphorylation of MEF2D by protein kinase A (PKA) determines the interact ion of the 
transcriptional factor with class II HDACs, mediating MEF2 transcriptional repression 
(Sebastian et al., 2013).  
MEF2 family members undergo also to tissue-specific alternative splicing in the transactivation 
domain, changing the regulation of MEF2 factors and producing a greater diversity of MEF2 
functions.  
Many calcium-regulated protein kinases also modulate MEF2s activities through the association  
with intermediary factors. Calmodulin and CaMK can activate MEF2 by repressing its 
repressors, respectively cabin and HDACs. Calmodulin, when activated by calcium, binds cabin 
on the MEF2 binding domain, thus impeding interaction with the transcription factors. When 
activated, the cabin inhibits MEF2 by recruiting class I HDACs inhibiting calcineurin and 
preventing the interaction between MEF2 and ERK5 (Youn et al., 1999)(H G Kasler et al., 
2000).  
MEF2 activity is also regulated through many protein phophatases. Among them, calcineurin can 
directly stimulate and active MEF2-dependent transcription, dephosphorylating NFAT and 
recruiting p300 (Wu et al., 2000)(Grégoire et al., 2006).  
MEF2 proteins are also modified by sumoylation on conserved lysine residues (Grégoire et al., 
2006)(Kang et al., 2006)(Riquelme et al., 2006)(Zhao et al., 2005). This post-translational 
modification, which occurs on lysine 391 in MEF2C and on lysine 439 in MEF2D inhibits 
transcriptional activity and it is mediated by class IIa HDACs (Grégoire et al., 2006). 
Recent studies have identified a novel post-translational modification. MEF2D activity is 
regulated by lysine 267 methylation in the transactivation domain, as operated by the co-
repressor G9a. G9a controls and represses MEF2 activity during skeletal muscle differentiation 
through its interaction with cabin and HDACs (J. Choi et al., 2014). 
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The acetylation of MEF2 is also required for efficient DNA binding (K. Ma et al., 2005). The 
histone acetyltransferases (HATs) p300, PCAF, and CBP acetylate MEF2 proteins on lysine 
conserved residues in the MADS-domain (K. Ma et al., 2005), promoting MEF2 activity. The 
MADS-domain is also critical for the interaction of MEF2 with class IIa HDACs, repressors of 
MEF2 activity. In this manner the cells can operate by providing a model of dual mutually 
exclusive signaling for MEF2, important for the regulation of different biological outputs such as 
differentiation and growth (Timothy A. McKinsey et al., 2002). 
 
Modulation of MEF2 activity by class IIa HDACs. 
 
Class IIa HDACs are widely recognized as the most important transcriptional repressors of genes 
regulated by MEF2 (Timothy A. McKinsey et al., 2002). Class IIa HDACs act by binding to the 
MEF2/MADS-domain, without affecting the DNA binding, thus promoting the formation of 
multiproteins repressive complexes on the regulatory regions of MEF2-dependent genes. Class 
IIa HDACs lead to suppression of transcription through multiple mechanisms: the exclusion of 
transcriptional co-activators such as p300/CBP in a sort of competitive binding, or by recruiting 
class I histone deacetylases, which can deacetylate and switch off  MEF2s, as in the case of 
HDAC3 that binds the complex N-CoR/SMRT (Lu et al., 2000)(Grégoire et al., 2006)(A. Han et 
al., 2005). Phosphorylation cascades affect MEF2 activity by modifying interactions with their 
co-repressors. In response to developmental and pathological signaling phosphorylation of class 
IIa HDACs on conserved serine residues creates docking sites for the intracellular chaperone 
proteins 14-3-3, promoting the export of histone deacetylases out of the nucleus into the 
cytoplasm. This re- localization results in the subsequent activation of MEF2 transcription (Wang 
et al., 2000)(S. J. Choi et al., 2001)(Clocchiatti et al., 2011)(Di Giorgio et al., 2014)(Figure 2). 
The interaction of MEF2s with HDACs works as a switch in several contexts during both 
adaptive and differentiative responses as, for example, in the regulation of skeletal muscle 
differentiation (T A McKinsey et al., 2000). 
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Figure 2: Repression of the transcriptional activation of MEF2 by class IIa HDACs. 
Image adapted from (Timothy A. McKinsey et al., 2002). 
 
 
The histone deacetylase (HDAC) family.  
 
The human genome encodes for eighteen different histone deacetylases (HDACs), which are 
grouped in four different classes on the basis of sequence homology to yeast counterparts, 
different catalytic activity, subcellular localization and interacting partners (Xiang-Jiao Yang and 
Seto, 2008).   
 Class I HDACs includes HDAC1, -2, -3, and -8 that present a high homology with yeast 
enzyme Rpd3, are expressed ubiquitously across cell types, have mainly a nuclear 
localization and exert a high catalytic activity versus histone and non-histone substrates. 
 Class II HDACs are subdivided into class IIa (HDAC4, -5, -7, and -9) and class IIb 
(HDAC6, and -10). These deacetylases are structurally related to yeast HDA1, they can 
shuttle between the nucleus and the cytoplasm in a phosphorylation state-dependent 
manner and they have a tissue-specific pattern of expression. 
 Class III HDACs includes the Sirtuins (SIRT1-7), which are homologous to yeast Sir2 
and are localized in different cellular compartments.  
 Class IV HDACs is composed only by HDAC11 that shares homology and displays 
common characteristics with both class I and class II (Figure 3).  
HDACs are enzymes known to play an important role in the regulation of gene expression both 
in physiological processes, such as cell proliferation and differentiation, and pathological 
conditions (Barneda-Zahonero and Parra, 2012). In addition to histones, an increasing list of 
Differentiation
 stimuli
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other non-histone proteins can also be deacetylated by HDACs, including transcription factors, 
chaperones, as well as different regulators involved in several different cellular processes (Peng 
and Seto, 2011)(X-J Yang and Seto, 2007). Since HDACs do not directly bind to DNA 
sequences, histone deacetylases are recruited to chromatin, after interactions with specific 
transcription factors to assert their repressive effect.  
 
 
 
 
 
Figure 3: The histone deacetylase family.  
The histone deacetylase family is subdivided into four different subclasses according to sequence 
homology to yeast prototypes, subcellular localization, different catalytic activity and interacting 
partners (adapted from Barneda-Zahonero and Parra, 2012). 
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Class IIa histone deacetylases: function and structure. 
 
Class IIa HDACs, which comprises HDAC4, -5, -7, and -9, are expressed in many different 
tissues such as brain, skin, skeletal, cardiac and smooth muscle, bone, cardiovascular and 
hematopoietic system, and are involved in different developmental and differentiation processes 
(Clocchiatti et al., 2011).  
Unlike other HDACs, class IIa histone deacetylases present a peculiar structural organization. 
This is appreciated by a bipartite organization consisting of two distinct regions: an extended N-
terminal regulatory domain and a C-terminal catalytic domain (Haberland et al., 2009). The N-
terminal region (~450–600 amino acids) is involved in different regulatory functions. It mediates 
protein–protein interactions with a variety of DNA-binding transcription factors, transcriptional 
co-repressors and chaperone proteins (M. Martin et al., 2007)(Verdin et al., 2003), among them 
MEF2 TFs are the best characterized. The N-terminal adaptor domain contains also a nuclear 
localization signal (NLS) and several serine residues, which are subject to phosphorylation, a 
post-translational modification that regulates the subcellular localization of these enzymes (T A 
McKinsey et al., 2001). The conserved C-terminal domain (~400–450 amino acids) of class IIa 
HDACs contains the catalytic deacetylase domain (HDAC domain) and a nuclear export signal 
(NES)(M. Martin et al., 2007)(Figure 4). 
Unlike other members of HDAC family, class IIa members have a weak intrinsic HDAC activity 
because of a substitution of a tyrosine residue in the catalytic site, highly conserved among class 
I enzymes, with a histidine (Lahm et al., 2007). HDAC activity of class IIa members is 
dependent on the formation of a multiprotein repressor complex at the C-terminal domain, which 
comprises HDAC3, the co-repressors SMRT (silencing mediator for retinoid and thyroid 
hormone receptor) and N-CoR (nuclear receptor co-repressor 1)(Fischle et al., 2002). 
 
MEF2 as a regulator of differentiation programs and growth.  
 
MEF2 factors are highly expressed in skeletal, cardiac and smooth muscle cells, as well as in 
neurons (Edmondson et al., 1994)(Lyons et al., 1995), and at lower levels in several other cell 
types. The MEF2 family of transcription factors plays important functions in tissue development 
and homeostasis both in embryonic tissues and in fully differentiated tissues. In developing 
tissues, such as bone tissue, muscle and nervous system, the expression of MEF2s marks and 
influences the beginning of the differentiation process and is inversely correlated with the 
repressive activity of class IIa HDACs (Arnold et al., 2007)(Lu et al., 2000)(Verzi et al., 2007). 
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The important and critical role of MEF2 factors in developmental processes of various tissues 
has been illustrated by loss-of- function mutations of each single MEF2 gene. Genetic studies in 
mice have proved the important contribution of MEF2A to the regulation of heart development 
(Naya et al., 2002). Likewise, defects in MEF2C impact on cardiovascular system, causing mice 
to die at stage E9.5 (Q. Lin, 1997)(Qing Lin et al., 1998). By contrast, homozygous mutations in 
MEF2D are viable, probably because of overlapping expression patterns with other MEF2 
members (Arnold et al., 2007). Conditional, cell lineage specific deletions of MEF2s have 
proved additional roles of these TFs during B-cells development (I. Debnath et al., 2013) and 
bone homeostasis (Collette et al., 2012)(Kramer et al., 2012). In adult tissues MEF2s regulate 
stress responses, such as cardiac hypertrophy (C. L. Zhang et al., 2002)(Potthoff et al., 2007), 
remodeling programs, cell survival and proliferation, for example, by stimulating apoptosis of 
thymocytes via Nur77 (Dequiedt et al., 2005) or of neurons (Bolger and Yao, 2005), and cell 
division, via activation of the transcription of c-jun by MEF2D (T. H. Han and Prywes, 1995). 
The ability of MEF2 proteins to control such diverse and opposing cellular decisions like 
differentiation, proliferation and apoptosis depends on their regulatory mechanisms, such as 
specific post-translational modifications and interactions with transcriptional co-factors and co-
regulators. 
 
The MEF2-class IIa HDACs axis regulates differentiation programs and cell growth.  
 
MEF2 proteins and class IIa HDACs are co-expressed in several, almost all cell types, including 
neurons, chondrocytes, muscle cells and lymphocytes. The interaction and the balance between 
the repressive function of class IIa HDACs and the transcription-activating functions of MEF2 
factors play an important and essential role in regulating developmental and differentiation 
processes in different tissues. As mentioned above class IIa HDACs have a weak deacetylase 
activity and for this reason they principally act as a bridge between the enzymatically active 
transcriptional repressor complex (SMRT/N-CoR/HDAC3) and MEF2s to modulate and regulate 
the transcription of target genes implicated in tissues development and cell differentiation. 
Studies in mice, using both gain and loss-of-function approaches, have suggested that several 
tissue specific cellular programs are regulated by the MEF2-class IIa HDACs axis, such as 
myogenesis, cardiovascular development, bone formation, endothelial function and the 
development of the immune system. 
The first association between class IIa HDACs and MEFs was described in myocytes. During 
skeletal muscle differentiation the interaction of HDAC4, HDAC5 and HDAC9 with MEF2s 
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results in the repression of MEF2 activity and suppression of myogenesis (Lu et al., 
2000)(Haberland et al., 2007)(Potthoff and Olson, 2007). MEF2-class IIa HDACs axis has a 
functional role also in cardiomyocyte differentiation and cardiac hypertrophy (C. L. Zhang et al., 
2002). MEF2C controls and regulates the heart development through the expression of numerous 
cardiac structural and contractile proteins. HDAC5 and HDAC9 are active regulators of cardiac 
development by repressing MEF2s, Campta2 (calmodulin binding transcription activator 2) and 
Srf (serum response factor) transcriptional activities (Song et al., 2006). During chondrocyte 
differentiation, the maturation of immature chondrocytes to hypertrophic chondrocytes is 
controlled by parathyroid hormone-related peptide (PTHrP), which induces the 
dephosphorylation of HDAC4 and its translocation into the nucleus, resulting in the repression of 
MEF2 transcriptional activity (Arnold et al., 2007)(Potthoff and Olson, 2007). MEF2 factors 
control and regulate the development, differentiation and activation of thymocytes (T-cells) by 
association with transcriptional co-repressors, like HDAC7 and cabin, which inhibit Nur77 
expression in resting thymocytes (Parra et al., 2007)(Herbert G Kasler and Verdin, 2007). It has 
been shown an important contribution of the MEF2-HDACs axis in vascular integrity and 
remodeling. During embryogenesis MEF2 proteins regulate and promote endothelial cell 
survival, directly stimulating the expression of matrix metalloproteinase 10 (Mmp10), that 
degrades the extracellular matrix. HDAC7, which is highly expressed in endothelial cells during 
development, represses this activation, thus maintaining vascular integrity (Chang et al., 2006).  
 
MEF2-class IIa HDACs axis in cancer.  
 
Histone deacetylases (HDACs), together with histone acetyltransferases (HATs), are enzymes 
responsible for chromatin remodeling and thereby play an important role in gene transcription. 
Simply via MEF2 interaction, they are able to regulate cell proliferation, differentiation, 
apoptosis and many other cellular processes. Dysregulated MEF2-trascriptional activities due to 
alteration of class IIa HDACs and MEF2 factors interaction are observed in certain cancers (Di 
Giorgio et al., 2014)(Clocchiatti et al., 2011).  
In the last few years, numerous studies have demonstrated that alterations of the MEF2-class IIa 
HDACs axis appear to play a crucial role in cancer initiation and progression. For this reason 
there is an increasing interest in identifying and developing small molecules targeting the axis, in 
order to understand the functional relationships between the two players and to acquire 
knowledge to design, test and develop specific drugs for the treatment of cancer.  
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In acute myelogenous leukemia, high expression levels of MEF2C are correlated with the 
aggressive nature of this tumor (Schwieger et al., 2009). Activation of MEF2C has an oncogenic 
role also in human acute lymphoblastic leukemia (ALL)(Homminga et al., 2011). In 
hepatocellular carcinoma MEF2D is overexpressed and high expression levels of this 
transcription factor are associated with a poor prognosis (L. Ma et al., 2014). Recent results have 
discovered alterations in MEF2 levels and transcription in breast tumors (Schuetz et al., 2006) 
and the repressive activity of class IIa HDACs on  MEF2 transcriptional activity has been related 
to poor prognosis of a subset of these tumors. In particular in ER+ tumors, repression of putative 
MEF2-target genes correlates with aggressiveness and high class IIa HDACs expression is 
associated with reduced patients survival (Clocchiatti et al., 2013). By contrast, in recurrent ER- 
mammary cancers, expression of MEF2s correlates with NOTCH1 (Pallavi et al., 2012). 
Although some reports point to a contribution of MEF2-dependent transcription in the mammary 
gland neoplastic pathogenesis, data on the role of the MEF2-HDAC axis during normal gland 
development/homeostasis are lacking and only few information are available on the role 
accomplished by the axis in epithelial cells (Ishikawa et al., 2010).  
 
Morphogenesis and oncogenesis in the mammary gland. 
 
The mammary gland is an organ that presents a remarkable feature: its development begins 
during embryonic life but reaches the complete functional form only during adulthood. The 
study of morphogenetic processes not only contributes to answer key questions in developmental 
biology, but also contributes to our understanding of several cancer related features. In fact, 
several oncogenes significantly modify epithelial structures providing compensations and 
reverting morphogenetic signaling. For this reason the comprehension of how mammary 
epithelial units are formed, which signals are required and which targets they use to transmit 
these information are of valuable interest. To better understand the molecular and cellular 
mechanisms involved in developmental (formation and function) and pathological processes, it is 
necessary to take advantage from appropriate experimental research models aimed to reproduce 
the complexity of the mammary gland environment but that also permit simple manipulations 
and observations.  
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The mammary gland structure in development and cancer.  
 
The mammary epithelium is a bilayered polarized structure composed of an inner layer of 
luminal epithelial cells, facing the lumen, immediately surrounded by an outer layer of 
myoepithelial cells (Mina J. Bissell et al., 2002). Given this organization the epithelial luminal 
cells do not directly contact the basement membrane and the stroma (Figure 4).  
 
                                             
 
Figure 4: Schematic representation of the structure of mammary epithelium.  
 
 
The mammary epithelial tree is embedded in a complex stroma, where several different cell 
types participate like adipose and immune cells, fibroblasts and endothelial cells (Hansen and 
Bissell, 2000)(Weigelt and Bissell, 2008). Two cellular compartments contribute to the 
development of the mammary gland: the epithelial and the stromal, both arising from differe nt 
origin during embryonic life, the ectoderm and the mesoderm respectively. In the mouse 
ectodermal placodes form around embryonic day 10 and organize linearly, giving rise to the so 
called milk line (Robinson, 2007). The placodes evolve in buds, which continue to grow with the 
stimulation of the underlying mesenchyme. At birth, cell proliferation and branching activities 
govern the generation of a small ductal tree. This rudimental structure remains silent up to 
puberty when, under the influence of sexual hormones, epithelial cells manifest a significant 
ductal growth and branching in the stroma (Smalley and Ashworth, 2003). The adult mammary 
gland is now composed of an extensive network of ducts that branches out in smaller ductules 
and terminates in lobules. In the human gland the lobules end forming the terminal ductal lobular 
unit (TDLU)(Visvader, 2009). It is only with pregnancy that, under the influence of additional 
hormonal stimulation, the mammary tree undergoes an extensive proliferation burst followed by 
a terminal differentiation that results in milk secretion (L Hennighausen and Robinson, 
2001)(Figure 5). 
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Figure 5: Evolution of the mammary gland. 
Schematic representation of different stages of the mammary gland development from puberty to 
pregnancy and lactation (adapted from Lothar Hennighausen and Robinson, 2005). 
 
 
The analysis of the structure of the mammary gland is of relevance also for pathological 
processes. In fact, to establish a correct diagnosis and eventual prognosis of breast carcinoma, 
pathologists rely on two different parameters: the degree of architectural disorder and the 
variability in size and shape of cells and nuclei. This classification, that differs from the 
canonical TNM (tumor dimension and presence of lymph node and distant metastasis), has 
proven useful in predicting the mammary and prostate cancer aggressiveness and is generally 
called grading (American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed. 
New York, NY: Springer; 2010). In particular this system is based on the identification of:  
 Architectural maintenance, which describes how much the neoplasm preserves the 
original ductal/lobular structure. The loss of basement membrane integrity and presence  
of cancer cells in the stroma identifies invasive carcinoma. Conversely, premalignant 
lesions, confined within an integral basement membrane, are classified as Ductal 
Carcinoma In Situ (DCIS). However these structures may manifest different degree of 
luminal filling and the presence of a necrotic centre.  
 Nuclear appearance, which evaluates the degree of alterations of the nuclear shape and 
size in histological sections. 
 Proliferation index and counts the number of actively dividing cells, which generally is 
dependent on the Ki67 staining. 
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Defining the appropriate research model.  
 
Over the years, biological research has contributed significantly to the understanding and 
answering important questions through the use of in vitro cell culture in a monolayer and with 
animal models. These experimental approaches have been particularly useful for mammary 
gland development and breast cancer. Both systems have some limitations and in vivo studies 
can pose ethical constrains. 
Conventional cell culture has been useful for the identification of dysregulated pathways, given 
the wide number of cancer cell lines established, their simple manipulation and propagation. 
Additional advantages are the relative low costs and a quite high level of reproducibility. 
Moreover, cancer cell lines frequently display alterations commonly found in human tissue 
neoplastic specimens and recapitulate the great heterogeneity found in primary neoplasms (Neve 
et al., 2006). However common cell lines are generally established from metastasis and may not 
reflect the properties of primary tumors, as evidenced for ER+ breast tumors. Moreover, 
conventional in vitro culture models create an environment for the cells that markedly differs 
from the microenvironment that is present in tissues in vivo (Gogola et al., 2007), loosing many 
characteristics and cues that could have important influences in tissue morphogenesis and 
function (Mina J. Bissell et al., 2002). In vivo cells are organized in three-dimensional structures, 
where they are dependent on the ECM and the neighboring cells. Plastic has long been 
recognized as a stiffer substratum compared to the physiological matrix found in mammary 
gland.  
The use of mouse models to study mammary gland development and cancer has given invaluable 
results. Generation of genetically modified animals permitted the identification of several 
transcription factors required for embryonic development like Lef1 and Tbx3, during puberty 
like the ER or for mammary terminal differentiation as STAT5a (Reichenstein et al., 2011). 
Moreover, they also significantly contributed to understanding the effect of commonly found 
alteration as TP53, HER2 or MYC (Jackson and Lozano, 2013)(Hutchinson and Muller, 2000), 
providing models that frequently recapitulate human histology in the context of preserved 
physiological architecture and cell-cell communication. Unfortunately, they are also associated 
with long time required for experimental observations, relatively reduced possibilities of samples 
manipulation and sometimes they do not permit basic molecular and biological observations, as 
for example, lumen translocation or precise metabolic measurements of oncogene expressing 
cells.  
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The three-dimensional cultures bridge the gap between a very simple and tractable model and a 
very sophisticated and elegant one. 3D cultures closely mimic the biological microenvironment 
and physiological cell-cell and cell-extracellular matrix interactions, reproducing and 
maintaining critical aspects of tissue architecture (growth, organization and differentiation), 
making these models attractive for studies on tissue morphogenesis and cancer. Three-
dimensional cultures have contributed significantly to the understanding of the complexity of 
cues that play a pivotal role in the organ morphogenesis. This achievement has been possible 
through the use of three-dimensional substrates for studying cell-cell and cell-extracellular 
matrix interactions. A common method utilized for this type of research is the cultivation of the 
cells in a reconstituted basement membrane matrix (rBM) derived from a special type of mouse 
tumor, the Engelbreth Holm-Swann (EHS) murine sarcoma, commonly referred to as Matrigel 
(J. Debnath et al., 2003). This proteinous gel is mainly rich in laminin and contains a lso other 
extracellular matrix components such as collagen, fibronectin, nidogen and proteoglycans  
(Kleinman et al., 1986), thus partially recreating a similar environment found for example in 
human mammary gland.  
Besides to these “monotypic” 3D culture models, other systems better mimicking in vivo 
conditions have been described and established over the years. For example epithelial cells can 
be co-cultured with other mammary gland cell types, enabling the investigation of cells-
extracellular matrix interaction effects in vitro, or transplanted into an ex vivo system, cleared fat 
pad (stroma tissue), or can be grown as whole organ culture in vitro (Schmeichel and Bissell, 
2003). 
 
3D morphogenic model of mammary gland. 
 
Mammary morphogenesis is characterized by the presence of several different instructive 
signals, which provide the correct stimulation to generate the proper glandular architecture. 
These structures transit from a disorganized state to an ordered epithelial organization 
modulating polarity, proliferation, and luminal cells clearance (J. Debnath and Brugge, 2005), 
which resemble events found in vivo. Specifically, the immortalized non transformed human 
mammary epithelial cell line, MCF-10A, is an example of a cell line capable of forming acinar-
like spheroids/structures, which are similar to those found in the mammary gland, when it is 
cultured on a reconstituted extracellular matrix, (J. Debnath et al., 2002). 
Initially, each single cell proliferates to generate a filled spheroid. During the first period 
epithelial cells are characterized by a rotational motion, with a complete revolution every four 
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hours. The movement is independent from cell proliferation, as it is still noticeable after 
treatment with mitomicin C and stops at day eight. Interestingly this motion is dependent on 
microtubules, as testified by nocodazole treatment, and by polarity proteins, like Scribble and 
PAR3, whose knock-down completely blocks this feature. Moreover the rotational movement 
seems to favor Golgi reorganization and apical side definition, events required for a proper cell 
polarization. At this point the structures present an outer layer of cells contacting the ECM, that 
manifest a correct apical-basal polarity, and an inner core of cells, lacking basement membrane 
contacts, that are subjected to a series of stress events and compensations. These eventually enter 
an apoptotic and a non-apoptotic cell death processes, or both (J. Debnath et al., 2002)(Mills et 
al., 2004). Curiously forced expression of anti-apoptotic proteins in MCF-10A cells (such as Bcl-
2 or Bcl-xL) does not prevent lumen formation, but only delays it appearance (J. Debnath et al., 
2002). These observations suggest that additional events take place to ensure the correct acinar 
morphogenesis. Moreover cells not in direct contact with the matrix perceive an increase 
metabolic stress, related to a depletion in glucose uptake. These matrix orphan cells manifest 
increase in ROS production and stimulate autophagy which, interestingly, is stimulated by the 
up-regulation of TRAIL (Mills et al., 2004). ROS inhibition with scavengers like Trolox or N-
acety-L- lcysteine (NAC) confers a protection from cell death in Bcl-2 overexpressing cells, 
indicating that metabolic impairment may plays a role in luminal cell survival (Schafer et al., 
2009). Autophagy seems to be a primary response to cell detachment and provides an initial 
strategy for survival of these matrix deprived cells. Accordingly inhibition of the autophagic 
machinery or depletion of central ATG genes fosters luminal cell death in the acinar lumen 
(Fung et al., 2008). 
An interesting link between lumen formation and matrix detachment involves integrin signaling.  
Integrins play a key role at different steps of this morphogenetic process (Reginato et al., 
2003)(Lee and Streuli, 2014). The absence of integrin-mediated pro-survival signals (anoikis) 
negatively affects the expression of the pro-survival RTK epidermal growth factor receptor 
(EGFR), which is internalized and degraded (Reginato et al., 2003). This creates an imbalance 
between apoptotic and non-apoptotic members as the expression and activity of pro-apoptotic 
factors like Bim and Bmf  increase (Reginato et al., 2005)(Schmelzle et al., 2007), which results 
in cell death. Interestingly recent evidences support a role for integrin dependent lumen 
formation, which is independent from apoptosis but rather involves the formation of a correct 
polarization process (Lee and Streuli, 2014). In particular beta-1 integrin collaborates with 
microtubules to ensure a spatial reorganization of the Golgi apparatus and to define the 
basolateral surface, by removing tight junctions. This discovery made on primary cells 
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corroborates a previous finding where beta-1 integrin blockage using specific antibodies 
suppressed acinar polarization (Nedvetsky et al., 2012). The control in junctional proteins seems 
to be achieved through the control of endocytic trafficking, which is generally influenced by the 
microtubule network. It is curious to note that not only altered integrin signaling but also a 
modification of environmental stiffness, which differentially engages integrins, modulate s lumen 
formation. In fact, in MCF-10A cells cultured onto a collagen matrix, which is stiffer compared 
to laminin, the apoptotic and non-apoptotic death responses were completely abrogated. This 
altered response generated acinar structures that remain without cavity (Butcher et al., 2009). In 
addition the abrogation of the function of other players, needed to establish epithelial polarity, 
significantly impacts on lumen formation. The deregulation of Scribble, a component of the 
protein machinery needed to define the basolateral surface, perturbs not only Golgi disposition 
but also the luminal clearance (Godde et al., 2014). Its loss is even capable of blocking myc 
induced apoptosis in MCF-10A cells cultured in 3D. Similarly loss of LKB1, a master kinase 
regulating PAR3 and apical side determination, blocks cell polarization and confers resistance to 
luminal cell death (Klefstrom et al., 2007). Although signals provided by the extracellular 
microenvironment are necessary to determine the complete morphogenesis, also the medium in 
which cells grow exerts an important contribution. Generally MCF-10A cells are routinely 
cultured with cholera toxin, an agent that stimulates cAMP production. Removal of this 
component from the medium results in filled structures (Nedvetsky et al., 2012). This effect is 
dependent on a decreased Bim expression and to a decreased pERK signaling. ERK 
phosphorylation was previously identified as an important signal that modulate the response to 
anoikis (Reginato et al., 2003) and its down-regulation favors cell survival. Interestingly cAMP 
stimulation has an effect on α6- integrin, promoting its recruitment towards the ECM, an event 
linked to cell polarization.  
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Figure 6: Formation of the MCF-10A mammary epithelial acinus in 3D culture. 
Schematic representation of the processes that take place after seeding MCF-10A cells within 
ECM: at the beginning cells undergo a few cycles of proliferation, forming small spheroids. Next 
the outer layer of cells in direct contact with ECM develops an axis of apicobasal polarity, while 
the centrally localized cells lacking the necessary signals from the matrix die through both 
apoptotic and non-apoptotic processes, leading to lumen formation (adapted from J. Debnath and 
Brugge, 2005). 
                  
 
Modeling breast tumorigenesis in 3D culture. 
 
The epithelial tissues are structures of polarized and specialized cells, strictly organized by cell-
cell contacts. The disruption of normal tissue architecture is frequently associated to a 
dysregulated control of proliferation and altered cell survival (J. Debnath et al., 2003)(M J 
Bissell, 2007). The 3D cultures have been used extensively as experimental model systems to 
investigate and study the roles and effects of cancer genes and pathways associated with breast 
cancer progression (J. Debnath and Brugge, 2005). 
Initially observations were focused on the understanding of the role of characterized mutations 
and activated pathways in breast tumors. One of the features of neoplastic cells is the 
unrestrained proliferation. In this light initial work was carried out to address the specific 
consequences of boosting cell cycle in mammary epithelial cells in 3D cultures. The rational of 
this approach finds justification by the fact that cyclin D is also frequently amplified in breast 
cancer (Gillett et al., 1994)(Bartkova et al., 1994). Overexpression of the pro-proliferative factor 
cyclin D1 (CCND1) increases proliferation in MCF-10A 3D structures, which results in larger 
acini, but does not lead to luminal filling due to a compensatory increase in luminal apoptosis (J. 
Debnath et al., 2002)(Shaw et al., 2004). Inhibition of apoptosis or an increase in cell 
proliferation alone are not sufficient to alter and prevent luminal clearance; instead the 
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combination of the two alterations does not lead to the formation of a hollow lumen (J. Debnath 
et al., 2002). 
Similarly inactivation of critical cell cycle checkpoint proteins, such as the retinoblastoma 
protein Rb by the E7 viral product of human papilloma virus, leads to a similar phenotype with 
increased growth but hollow lumen and with MYC overexpression (J. Debnath et al., 2002). A 
frequent oncogenic event in breast cancer is represented by the loss or the mutation of the master 
regulator TP53. TP53 knock-down is associated with a reduced luminal cell clearance and 
related to an altered establishment of polarity. Similarly, overexpression of mutant versions of 
p53 promotes luminal cell filling related to a decrease in apoptotic proteins like Bax and Puma 
(Y. Zhang et al., 2011). Depletion of mutant p53 in breast cancer cell lines cultured onto laminin 
rich gels restores the correct round shape morphology with a hollow cavity (Freed-Pastor et al., 
2012). Interestingly, the mutant p53 effect is related to its ability to associate with SREBP 
transcription factors and foster the mevalonate pathway, which is highly activated in human 
breast cancer samples harboring p53 mutations. Pharmacological inhibition of this pathway 
mimics, at least partially, the effect of mutant p53 knock-down and restores a normal 
architecture. 
An additional frequent lesion, associated with poor prognosis is the amplification of the HER2 
oncogene, a tyrosine kinase receptor member of the EGF pathway (Sørlie et al., 2001). HER2 
overexpression in normal mammary epithelial cells cultivated in 3D significantly compromises 
the acinar morphogenetic program (Muthuswamy et al., 2001). In MCF-10A cells that express an 
inducible version of ErbB2/HER2, its activation even in growth-arrested, polarized acini resulted 
in a re- initiation of proliferation and formation of multi-acinar structures with luminal filling 
(Muthuswamy et al., 2001). Interestingly HER2 is capable of fostering cell growth even when 
just a single cell is overexpressing in the context of a well formed, resting acinar structure. 
Differentially, sporadic up-regulation of MYC, CCND1, E7 or AKT are incapable of producing 
growth, indicating that the environmental and structural architecture are posing a barrier to 
luminal outgrowth at early stage (Leung and Brugge, 2012). To achieve this effect HER2 not 
only boosts cell proliferation but also favors luminal cell translocation dependent on the 
stimulation of the MAPK activity. Furthermore to reach a filled lumen, HER2 disrupts cell 
polarity through the direct binding of Par6. Disruption of HER2-Par6 interaction does not impair 
cell proliferation but restrains its effect on cell survival indicating the need of coupling apoptotic 
resistance to cell proliferation to generate filled acinar structures (Aranda et al., 2006). Of note, 
MCF-10A cells overexpressing HER2 resemble ductal carcinoma in situ (DCIS) lesions but are 
not associated with invasion. In human samples HER2 and 14-3-3z are often co-expressed in 
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invasive breast cancer. 14-3-3z in combination with HER2 influences epithelial features by 
favoring epithelial mesenchymal transition (EMT) and therefore migration. This effect is 
dependent at least in part by the activation of the transforming growth factor beta (TGF) 
signaling pathway, caused by an increased expression of TGF1 receptor. It should be noted that 
14-3-3z overexpression does not stimulate cell proliferation but affects luminal cell clearance by 
affecting the levels of p53. In particular its down-regulation seems to be dependent on the 
increased expression of MDM2, stimulated by the enhanced activity of pAKT.  
In epithelial cancer increased activity of the phosphoinositide (PI) 3-kinase pathway is a frequent 
event and in breast cancer samples PI3K is frequently mutated. Moreover overexpression of 
receptor tyrosine kinases (RTK) like HER2 impinges on the signaling, by enhancing its activity. 
Overexpression of a mutant form of PI3K H1047R in MCF-10A cells leads to the formation of 
bigger multi-acinar structures (Chakrabarty et al., 2010). Curiously activation of PI3K does not 
suppress the autophagic program in cells cultured in 3D. The knock-down of basic autophagy-
related genes (ATG), like Atg7 and Atg12, in this context is followed by a concomitant increase 
in cell death, further indicating that autophagy in this model is primarily a pro-survival response. 
However, the concomitant increase in cell death is paralleled by a massive burst in proliferation 
as a result of an increase in ERK-MAPK activation. AKT activity in 3D cultures, using an 
inducible model, demonstrated this downstream arm is able to increase acinar size and can delay 
apoptotic clearance but does not confer luminal filling phenotype.  
Abrogation of PI3K signaling in cancer cells is generally associated with a 
homeostatic/resistance response, which involves the up-regulation of RTKs expression to 
balance the inhibition of the pathway (Chandarlapaty et al., 2011). Pharmacological inhibition of 
PI3K in cancer cell lines cultured in 3D leads to a dichotomous response where matrix deprived 
cells undergo cell death while matrix attached survive (Muranen et al., 2012). Abrogation of this 
signaling pathway is associated with feedback loop responses that up-regulate EGFR and Bcl2. 
Particularly interesting is Bcl2 because its synthesis appears in a condition in which normal CAP 
dependent translation is inhibited (PI3K inhibition). Restraining from this block is possible 
because of the presence of an IRES motif in the 5’ UTR of the Bcl2 transcript. Concomitant 
inhibition of PI3K and Bcl2 elicits massive cell death and disintegration of acinar structures 
made by cancer cell lines but not in the case of untransformed cells like MCF-10A. These 
findings not only point to this drug combination as efficient anti-cancer treatment to eradicate 
neoplastic cells but also underline how the use of 3D cultures can be extremely useful to better 
understand compound sensitivity and to discover mechanisms of resistance to targeted 
therapeutics, not achievable with conventional standard cultures.  
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Cell cultures and reagents.  
 
Human normal immortalized epithelial breast cells (MCF-10A) and MCF-10A cells expressing 
HER2 were maintained in Ham’s F12/DMEM 1:1 medium (Sigma-Aldrich) supplemented with 
5% horse serum (Gibco), penicillin (100U/ml), streptomycin (100µg/ml), L-glutamine (2mM) 
(Lonza), insulin (0,01mg/ml), hydrocortisone (500ng/ml), cholera toxin (100ng/ml)(Sigma-
Aldrich), and epithelial growth factor (20ng/ml)(Peprotech). HEK-293T cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS), L-glutamine (2mM), penicillin (100U/ml), and streptomycin (100µg/ml)(Lonza). Cells 
expressing inducibile forms of MEF2 and HDAC7 were grown in complete F12/DMEM medium 
without phenol red (Sigma-Aldrich) and with 5% charcoal stripped horse serum. The proteasome 
inhibitor bortezomib (LC Laboratories) was used at 250nM for 8h. The lysosomal/autophagy 
inhibitor cloroquine (Sigma-Aldrich) was used at 10µM for 8h. The CRM1 inhibitor, 
leptomycin-B (LC Laboratories), was used at 5ng/ml. 4-hydroxytamoxifen (4-OHT)(Sigma-
Aldrich) was used at 1µM. The inhibitor of HER2 lapatinib (LC Laboratories) was used at 1µM 
for 2h. 
 
Three-dimensional morphogenetic assay.  
 
3D morphogenetic assays were conducted as previously described (J. Debnath et al., 2003). 
Briefly, to obtain mammospheres, cells (3x104) were plated in a thick layer of ~1-2mm of 
laminin-rich extra-cellular matrix (Cultrex-Trevigen). Cultrex was overlaid with cells grown in 
medium containing 5ng/ml EGF along with 2%v/v cultrex. Cells were maintained at 37ºC and 
5%CO2 and the culture medium was changed every 4 days. Images of mammospheres were 
collected by using a Leica AF 6000LX microscope. Acinar area measurements were determined 
using Volocity 3D image analysis software.  
 
Plasmid construction, transfection, retroviral and lentiviral infection, and silencing.  
 
pWZL-Hygro-MEF2C-VP16-ER was previously described (Di Giorgio et al., 2013). The ligand 
binding domain of ER was PCR amplified from pCDNA MEF2-VP16-ER (Flavell et al., 2006) 
and cloned in pWZL-Hygro. To generate pWZL-Hygro-HDAC7/SA-ER, an EcoRI fragment of 
HDAC7/SA point mutant (Di Giorgio et al., 2013) was cloned into pWZL-Hygro-ER. MCF-10A 
cells expressing MEF2-VP16-ER or HDAC7/SA-ER transgenes were generated by retroviral 
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infection as described previously (Cernotta et al., 2011). 293T packaging cells were transfected 
24h after plating by calcium-phosphate precipitation. After 48-72h the virus-containing medium 
was filtered and added to target cells. Recombinant lentiviruses (Sigma-Aldrich) were produced 
by tranfection of 293T cells. Briefly, subconfluent 293T packaging cells were co-transfected 
with 20µg of lentiviral vector plasmids, 15µg of pCMV-ΔR8.91, and 5µg of VSVG envelope 
plasmid by calcium-phosphate precipitation. After 24h medium was changed, and recombinant 
lentiviruses vectors were harvested 24-36h later.  
 
Immunofluorescence, antibody production and immunoblotting.  
 
For immunofluorescence, cells were fixed in 3% paraformaldehyde and permeabilized with 1% 
Triton-X100 in PBS for 15min. Next, coverslips were incubated with primary antibodies anti-
HDAC4 (Paroni et al., 2004), anti-HDAC7 (Santa Cruz Biotechnology), anti-MEF2D (BD 
Transduction Laboratories), and anti-GM130 (BD Transduction Laboratories). Then, they were 
incubated with 488-Alexa or 546-Alexa Fluor conjugated secondary antibodies (Life 
Technologies). Finally, coverslips were incubated for 15min with 5µM TOPRO-3 (Life 
Technologies) to label nuclei. Cells were imaged with a Leica confocal scanner SP equipped 
with a 488 λ Ar laser and a 543 to 633λ HeNe laser. Representative confocal images were shown 
as equatorial cross sections through the middle of acini.  
For antibody production, rabbits were immunized with recombinant histidine-tagged HDAC5 
fragment 1132-2040 purified from Escherichia coli. For anti-HDAC5 antibody purification from 
antiserum, HDAC5 was fused to glutathione S-transferase (GST) and cross- linked to 
glutathione-Sepharose as described previously (Paroni et al., 2001). 
Cell lysates after SDS-PAGE and immunoblotting were incubated with the following primary 
antibodies anti: HDAC4 (Paroni et al., 2004), HDAC7, MEF2A (Santa Cruz Biotechnology), 
MEF2D (BD Transduction Laboratories), AKT (Cell Signaling Technology), p53 (Santa Cruz 
Biotechnology), p62 (BD Transduction Laboratories), LC3 (Demarchi et al., 2006), VP16 (Santa 
Cruz Biotechnology), p120 (BD Transduction Laboratories), ERK, P-ERK (Cell Signaling 
Technology). Secondary antibodies were obtained from Sigma-Aldrich, and blots were 
developed with Super West Dura (Pierce). For antibody stripping, blots were incubated for 
30min at 60ºC in stripping solution containing 100mM β-mercaptoethanol. DNA staining was 
performed as described previously (Cernotta et al., 2011). For S-phase analysis, cells were grown 
for 3h with 100uM bromodeoxyuridine (BrdU). After fixation, coverslips were treated with 1N 
HCl (10min, in ice), followed by 20min with 2N HCl at room temperature. Mouse anti-BrdU 
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(Sigma-Aldrich) was used as primary antibody. Nuclei were stained with Hoechst 33258 (Sigma-
Aldrich). 
 
RNA extraction and quantitative qRT-PCR.  
 
Cells were lysed using RiboEx (GeneAll Biotechnology Co., LTD). 1 µg of total RNA was retro-
transcribed by using 100 units of M-MLV reverse transcriptase (Life Technologies). qRT-PCRs 
were performed using the Bio-Rad CFX96 apparatus and SYBR Green technology (Resnova). 
Data were analyzed with the ΔΔCt method, using GAPDH (glyceraldehydes 3-phosphate 
dehydrogenase) and HPRT (hypoxanthine phosphor-ribosyltransferase) as normalizer genes. All 
reactions were done in triplicate. To evaluate the mRNA copies/µg of retro-transcribed RNA for 
each class IIa HDACs, standard curves of qRT-PCR amplification were obtained using defined 
concentrations of the relative cDNAs. 
 
Chromatin immunoprecipitation.  
 
For immunoprecipitations, DNA-protein complexes were cross- linked with 1% formaldehyde 
(Sigma-Aldrich) in phosphate-buffered saline (PBS) for 15min at room temperature. After 
quenching and two washes in PBS, cells were collected and then lysed for 10min with lysis 
buffer (5mM PIPES, 85mM KCl, 0.5% NP-40) containing protease inhibitor cocktail (Sigma-
Aldrich). The pellets were resuspended in RIPA-100 and sonicated using Bioruptor UCD-200 
(Diagenode) with pulses of 30s for 15min, resulting in an average size of ~500 bp for genomic 
DNA fragments. Samples were pre-cleared and immunoprecipitated overnight with 1µg of anti-
HDAC7, followed by incubation with protein A beads (GE Healthcare Bio-Sciences) blocked 
with BSA and salmon sperm DNA (1µg/µl) at 4ºC for 2h. Beads and inputs were treated with 
proteinase K overnight at 68ºC to degrade proteins and reverse cross- linking. Genomic DNA 
finally purified with Qiagen QIAquick PCR purification kit and e luted in 100 µl of water. 
Graphic representation of the CDKN1A locus and its chromatin organization in human 
mammary epithelial cells was obtained from ENCODE (http://genome.ucsc.edu/ENCODE/). 
Analysis of putative binding site for MEF2D was carried out with JASPAR (jaspar.genereg.net/). 
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Cell cycle analysis. 
 
Before measuring, cells were detached by trypsin and fixed in 70% ethanol. After some washing  
cells were resuspended in PBS supplemented with 1% Triton-X100 and RNAse-A 100 ug/ml and 
incubated 30min at 37°C. DNA staining was performed incubating cells with propidium iodide 
at 50ug/ml for 45min at RT. Cells were then passed through a flow cytometer equipped with the 
Cell Quest software by using a 488-nm argon ion laser (FACScan, BD Biosciences). A minimum 
of 10.000 events per sample was analyzed. Data analysis was performed by FCS Express 4 Plus 
Research Edition software. 
 
Gene set enrichment analysis (GSEA).  
 
Analyses were performed using the GSEA software  
(http://www.broadinstitute.org/gsea/index.jsp). The list of MEF2-target genes was obtained from 
the Molecular Signature Database (http://www.broadinstitute.org/gsea/msigdb/index.jsp). 
Dataset for MCF-10A cells was obtained from GEO (http://www.ncbi.nlm.nih.gov/geo/) 
GSE26148 (Simpson et al., 2011). Human normal and  breast tumor samples were taken from 
Curtis and colleagues (Curtis et al., 2012) with accession number EGAS00000000083 deposited 
at the European Genome-Phenome Archive (EGA, http://www.ebi.ac.uk/ega/). 
 
Statistics.  
 
Results were expressed as means ± standard deviations of at least three independent experiments, 
except for CHIP experiments where standard error was used. Statistical analysis was performed 
using a Student’s t test with the level of significance set at P <0.05. Data from 3D acinar area 
measurement were determined using Volocity 3D image analysis software and analyzed using 
Non-parametric Mann-Whitney test (Prism GraphPad Software). Data were from at least three 
independent experiments. *P<0.05; **P<0.01; ***P<0.005.  
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Regulation of the MEF2-HDAC axis during acini morphogenesis. 
 
As a first step to investigate and study the role of the MEF2-HDAC axis in mammary epithelial 
morphogenesis, we compared expressed sequence tag (EST) profiles between skeletal muscle 
and breast tissue, for class IIa HDACs and MEF2A, C, and D (Fig. 1A). As expected, in skeletal 
muscle MEF2C, HDAC4, and HDAC5 are the most expressed members of each family. By 
contrast in breast tissue MEF2A, MEF2D, and HDAC7 are the uppermost expressed isoforms. 
Furthermore, Gene Set Enrichment Analysis (GSEA), using a signature of putative MEF2-target 
genes, suggests that MEF2-dependent transcription is positively modulated during MCF-10A 
acinar morphogenesis (Fig. 1B). Hence, we selected MCF-10A cells as model to investigate the 
role of the MEF2-HDAC axis during mammary epithelial morphogenesis. When plated on a 
laminin-rich extracellular matrix (3D culture), MCF-10A cells transit from an initial 
proliferative, disorganized state (Fig. 1C, day 4), evidenced by the presence of several mitotic 
figures per acinus (Fig. 1D) and by the random orientation of the Golgi, to a quiescent polarized 
condition, marked by Golgi re-orientation, formation of a hollow lumen, and the absence of 
mitotic figures (Fig. 1C, day 16, and 1D).  
qRT-PCR experiments showed that, although with different magnitudes, the mRNA levels of 
certain MEF2-target genes, KLF2, KLF4, NR4A1, END1, and RHOB, were augmented when 
the acinar morphogenesis was completed, at day 16 (Fig. 2A). Together with MEF2-target genes, 
MEF2D mRNA levels rise, as similarly described during muscle differentiation (Nebbioso et al., 
2009)(Sebastian et al., 2013)(Fig. 2B). The expression of HDAC5 and HDAC9 also increase 
during acinar developmental process, while HDAC4 and HDAC7 remain constant (Fig. 2B). The 
up-regulation of CDKN1A was selected as marker of growth arrest (Besson et al., 2008), 
whereas BMF and BIM sign the appearance of apoptosis (Mailleux et al., 2008).  
To clarify the apparent paradox of the MEF2-dependent transcriptional stimulation coupled to 
the up-regulation of HDAC5 and HDAC9 mRNAs, we carried out an absolute quantification of 
class IIa HDACs expression (Fig. 2C). This analysis suggests that in MCF-10A cells HDAC7 
and HDAC4 mRNA levels are largely dominant over the other class IIa deacetylases and 
therefore even a six fold increase in HDAC5 mRNA could be irrelevant in the context of the 
MEF2-dependent transcription. We also performed immunoblot analysis (Fig. 2D), which 
confirmed the up-regulation of MEF2D and HDAC5 during acinar morphogenesis and evidenced 
a dramatic down-regulation of HDAC7 levels. This drastic reduction of HDAC7 could explain 
the up-regulation of MEF2-dependent transcription. Since HDAC7 down-regulation was 
uncoupled to a decrease in mRNA levels, to gain insight on the mechanism entangled in such 
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task, MCF-10A cells grown for 4 or 16 days, under 3D conditions, were treated with bortezomib, 
to block proteasome-mediated degradation, and with chloroquine, to block lysosomal/autophagy 
degradation, or with a combination of both drugs. Although class IIa proteins can be target of the 
proteasome (Potthoff et al., 2007)(Cernotta et al., 2011), HDAC7 down-regulation was 
unaffected by both drugs (Fig. 2E), thus indicating that other proteolytic events or different 
mechanisms control HDAC7 protein levels during acini formation. 
Class IIa HDACs nucleo-cytoplasmic shuttling is under the influence of multiple signaling 
pathways (Xiang-Jiao Yang and Seto, 2008)(Clocchiatti et al., 2011), mainly described during 
tissue differentiation, such as skeletal myogenesis (T A McKinsey et al., 2000). We therefore 
investigated the subcellular localization of MEF2D, HDAC4 (Fig. 2F), and HDAC7 (Fig. 2G) in 
cells grown for 4 or 16 days under 3D conditions. MEF2D localizes in the nucleus and both 
deacetylases show either a nuclear and cytoplasmic distribution. Treatment of MCF-10A cells 
with leptomycin B promoted the nuclear accumulation of HDAC7, thus indicating that the 
deacetylase undergoes nucleo-cytoplasmic shuttling. Similar results were observed at 16 days 
and for HDAC4 (data not shown).  
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Figure 1: The MEF2-HDAC axis in mammary gland. 
A: Plots illustrating the frequency of EST tags for class IIa HDACs and MEF2s family members in skeletal muscle 
and breast tissue. 
B: GSEA analysis of a list of 900 putative MEF2-target genes in expression data from MCF-10A cells cultured in  
3D comparing day 8 with 16.  
C: Confocal images comparing the distribution of the Golgi apparatus, using GM130 marker (red), and nuclei 
(blue), using TOPRO-3 staining, between MCF-10A cells grown in 3D cu lture fo r 4 and 16 days. Images are shown 
in pseudocolors. Scale bars, 50 µm. 
D: Quantification of mitotic figures and luminal filling in acin i generated by MCF-10A cells grown in 3D for 4 or 
16 days. 
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Figure 2: Analysis of MEF2-dependent transcription and class IIa HDACs expression in MCF-10A 
breast epithelial cells during acinar morphogenesis.  
A: qRT-PCR analysis was performed to quantify mRNA levels of MEF2-target genes, of the cell-cycle inhibitor 
CDKN1A and of the pro-apoptotic genes BIM and BMF in MCF-10A cells grown in 3D culture for 4 and 16 days. 
Fold induction was calculated as the ratio relative to 4 days of culture.  
B: qRT-PCR was performed to quantify mRNA levels of class IIa members (HDAC4, HDAC5, HDAC7, and 
HDAC9) and MEF2 members (MEF2A, MEF2C, and MEF2D) in MCF-10A cells grown in 3D for 4 and 16 days. 
Fold induction was calculated as the ratio relative to 4 days of culture.  
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C: qRT-PCR analysis was performed to quantify mRNA levels of all class IIa members (HDAC4, HDAC5, 
HDAC7, and HDAC9) in MCF-10A cells. The expression was calculated as number of copies relat ive to µg of 
retrotranscribed RNA.  
D: Immunoblot analysis of MEF2 family members and class IIa HDACs in MCF -10A cells grown in 3D for 4 and 
16 days. Akt was used as loading control. 
E: Immunoblot analysis of HDAC7 levels in 3D culture of MCF-10A cells at 4 and 16 days treated or not with 
bortezomib or bortezomib in association with chloroquine for 8h. p53 was used as positive control for proteasome-
mediated degradation inhibition. p62 and LC3 were used as positive controls of blocking lysosomal/autophagy 
degradation. Akt was used as loading control. 
F: Confocal images illustrating the subcellular localization of MEF2D (red) and HDAC4 (green) in MCF -10A cells 
grown in 3D culture for 4 and 16 days. Images are shown in pseudocolors. Scale bars, 50 µm.  
G: Confocal pictures exemplifying the subcellular localization of HDAC7 in MCF-10A cells cultured in 3D for 4 
and 16 days and for 4 days treated or not with leptomycin-B for 1h. Nuclei (blue) were stained with TOPRO-3. 
Images are shown in pseudocolors. Scale bars, 50µm.  
 
 
MEF2D down-regulation does not affect acinar morphogenesis but elicits different 
compensatory mechanisms.  
 
To comprehend the role of MEF2 in mammary epithelial cells, we silenced MEF2D expression 
by shRNA lentiviral infection. We selected MEF2D because MEF2D is the highest expressed 
isoform in breast tissue (Fig. 1A) and its expression is up-regulated during morphogenesis (Fig. 
2B and D). Despite an evident down-regulation of MEF2D at protein (Fig. 3A) and mRNA 
levels (Fig. 3B) in MCF-10A cells expressing two different shRNAs, we did not evidenced any 
negative alteration in the expression of the MEF2-target genes (Fig. 3B). Instead unexpectedly, 
END1 mRNA levels were augmented (Fig. 3B). In cells with down-regulated MEF2D acinar 
morphogenesis appeared normal, as proved by scoring luminal filling per strucure and Golgi 
orientation, with the GM130 marker (Fig. 3C). We also evaluated whether the absence of 
MEF2D could influence the initial proliferation phase by measuring the acinar size. Here again 
MEF2D seems to be dispensable (Fig. 3D). The absence of evident phenotypes in cells silenced 
for MEF2D could be the consequence of redundancy and/or of compensatory mechanisms as 
observed in other contexts (N. Liu et al., 2014). In fact, MCF-10A cells with down-regulated 
MEF2D revealed an increase in MEF2A protein levels in association with a down-regulation of 
HDAC4 and HDAC5 (Fig. 3A). 
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Figure 3: Effects of MEF2D down-regulation on acinar morphogenesis. 
A: Immunoblot analysis of MEF2 family members and class IIa HDACs levels in MCF-10A  cells expressing two 
different shRNAs against MEF2D or a control shRNA. Akt was used as loading control.  
B: qRT-PCR was performed to evaluate mRNA levels of MEF2-target genes and of MEF2D in MCF-10A cells 
expressing the shRNA15 or the control shRNA and cultured in 3D for 16 days.  
C: Quantificat ion of luminal filling per structure and acini polarization, scoring Golg i orientation, in MCF-10A cells 
expressing the shRNA15 or the control shRNA and grown in 3D for 16 days. 
D: Acinar area (µm2) of individual acini, generated in 3D culture by MCF-10A cells expressing the shRNA15 or the 
control shRNA at 4, 8 and 12 days, plotted as a box plot.  
  
 
Unscheduled expression of MEF2 compromises cell proliferation and reduces acini size. 
 
To understand the contribution of the MEF2-HDAC axis in the context of mammary epithelial 
cells, we decided to use an alternative strategy. We introduced in MCF-10A cells a conditionally 
active form of MEF2 fused to VP16 virus activation domain and to the ligand binding domain of 
the estrogen receptor (Flavell et al., 2006), as a control a DNA-binding defective mutant 
(ΔDBD) was used (Fig. 4A). In 2D culture, activation of MEF2-VP16 by 4-hydroxytamoxifen 
(4-OHT), but not the control construct, efficiently promoted MEF2-target genes transcription 
(Fig. 4B). Importantly, the magnitude of induction perfectly mirrors changes observed during 
acini morphogenesis in 3D culture (compare fig. 4B and 2A). Induction of MEF2 transcription 
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by 4-OHT in 2D cultured MCF-10A cells has a profound effect on proliferation (Fig. 4C). This 
anti-proliferative effect was observed also when cells were grown in 3D culture. Time course 
analysis indicated that stimulation of MEF2 activity within the first four days constrains acinar 
size (Fig. 4D). At day 4, in the presence of an unscheduled MEF2 transcriptional activity, acinar 
structures are smaller and populated by a reduced number of cells (Fig. 4E and F). To understand 
if MEF2 elicits a growth repressive effect during different phases of acini formation, we 
selectively stimulated its activity for four days starting from day 4, 8, or 12. Boosting MEF2 
transcription from day 4 to 8 still interferes with the proliferation of MCF-10A cells, as 
evidenced by the reduced acini size (Fig. 4G), number of cells (Fig. 4H), and the dramatic 
decrease of mitotic activity (Fig. 4I). Noteworthy, activation of MEF2 during the next time 
intervals (8 or 12 days in culture) does not exert any effect on acinar diameter (Fig. 4J and K), 
cells number, or luminal cell death (data not shown), thus indicating that MEF2 perturbations are 
principally linked to the initial proliferative phase of the morphogenetic process. Overall these 
data suggest that, in order to proceed with a normal morphogenetic process in mammary 
epithelial cells, MEF2 transcriptional activity must be limited during the initial proliferative 
state.  
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Figure 4: MEF2 transcriptional activity can compromise cell proliferation and acini size during the 
normal morphogenetic process in mammary epithelial cells. 
A: Immunoblot analysis of MEF2-VP16-ER levels in MCF-10A cells expressing MEF2-VP16-ER ch imera or its 
mutant defective in DNA binding MEF2-ΔDBD-VP16-ER. MEF2-VP16-ER-dependent transcription was induced 
by treating cells with 4-OHT for 24h. p120 was used as loading control. 
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B: mRNA levels of selected MEF2-target genes were measured by using qRT-PCR in MCF-10A cells expressing 
MEF2-VP16-ER or the mutant MEF2-ΔDBD-VP16-ER following 4-OHT treatment in 2D cu lture.  
C: Quantitative analysis of cell proliferation of MCF-10A cells expressing the two MEF2 inducible forms. The day 
after seeding, 4-OHT was added to culture medium and cells number scored 24h later. 
D: Time course analysis of acinar area (µm2) for the indicated times, as generated by MCF-10A cells expressing the 
two MEF2 inducible forms. The day after seeding, 4-OHT was added to the culture medium. 
E: Acinar size  (µm2) of MCF-10A cells, expressing the two MEF2 chimeras, in 3D culture for 4 days were 
analyzed. The day after seeding, 4-OHT was added to culture medium. 
F: Number of nuclei per acinus as generated by the different transgenic MCF-10A cells after 4 days in 3D cu lture.  
G: Acinar size (µm2) of MCF-10A cells, expressing the two MEF2 chimeras, in 3D cu lture for 8 days were 
analyzed. The fourth day in culture, 4-OHT was added to culture medium. 
H: Number o f nuclei per acinus as generated by the different transgenic MCF -10A cells after 8 days in 3D culture. 
I: Number of acin i with mitotic figures, as generated by the different transgenic MCF-10A cells after 8 days in 3D 
culture. 
J: Acinar size (µm2) of MCF-10A cells, expressing the two MEF2 inducible forms, in 3D culture for 12 days were 
analyzed. 4-OHT was added to culture medium as ind icated.  
K: Acinar size (µm2) of MCF-10A cells, expressing the two MEF2 inducible forms, in 3D culture for 16 days were 
analyzed. 4-OHT was added to culture medium as ind icated.  
 
 
Sustained HDAC7 activity promotes cell proliferation and affects acinar morphogenesis. 
 
The demonstration of a role of MEF2-dependent transcription in limiting proliferation of 
mammary epithelial cells suggests that the down-regulation of HDAC7, observed during the 
morphogenetic process could be instrumental to drive the exit from the cell cycle. To verify this 
hypothesis we generated MCF-10A cells expressing a conditionally active form of HDAC7, 
fused to the ligand-binding domain of the estrogen receptor (Fig. 5A). This mutant, named 
HDAC7/SA-ER, presents the substitution of four serine residues with alanines, in the amino-
terminal region. These serines once phosphorylated by various kinases become binding sites for 
14-3-3 proteins and are required for the efficient nuclear export o f the deacetylase (M. Martin et 
al., 2007)(Xiang-Jiao Yang and Seto, 2008). Hence, upon 4-OHT treatment, this chimera should 
promptly accumulate in the nucleus and repress MEF2-dependent transcription. Figure 5A shows 
that the fused protein is expressed at the expected size and, after 4-OHT addition to MCF-10A 
cells in 2D culture, it efficiently accumulates in the nucleus (Fig. 5B). Moreover, HDAC7/SA-
ER effectively represses MEF2-dependent transcription, as evidenced by the decrease in RHOB 
mRNA levels after eight days in 3D culture (Fig. 5C). To determine the effect of an unscheduled 
HDAC7 repressive activity during morphogenesis, we observed acinar size at 4, 8, and 12 days 
in 3D culture after induction with 4-OHT. Acini generated by MCF-10A cells expressing 
HDAC7/SA-ER are bigger at all time points analyzed (Fig. 5D). This raise in size depends on an 
increase in the number of nuclei per acinus (Fig. 5E). The increased number of epithelial 
structures presenting the lumen partially filled (Fig. 5F and quantitative analysis in fig. 5G) 
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confirmed the pro-growth effect of HDAC7. However HDAC7/SA-ER acini were also 
characterized by higher picnotic and fragmented nuclei (Fig. 5F arrows and quantitative analysis 
in fig. 5H), pointing to an increase in the apoptotic activity, as a counterbalance to restrain 
excessive proliferation. These data indicate that although HDAC7 can stimulate epithelial cell 
growth, compensatory mechanisms are engaged that limit this potential harmful effect.  
 
 
                 
 
Figure 5: Sustained HDAC7 activity promotes cell proliferation and affects acinar morphogenesis. 
A: Immunoblot analysis of transgene HDAC7 levels in MCF-10A cells expressing a mutant form of HDAC7 
defective in the four serine residues, binding sites for 14-3-3 proteins (HDAC7/SA-ER). HDAC7/SA-ER activ ity 
was induced by treating cells with 4-OHT for 24 h. AKT was used ad loading control. 
B: Confocal p ictures of MCF-10A cells showing HDAC7/SA-ER nuclear accumulat ion (green) after the induction 
with 4-OHT. Nuclei were stained with Hoechst 33258.  Images are shown in pseudocolors. 
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C: mRNA expression levels of the MEF2-target gene RHOB were measured by using qRT-PCR in MCF-10A cells 
expressing HDAC7/SA-ER or control grown in 3D culture for 8 days. 4-OHT was added to culture medium the day 
of seeding and the fourth day of culture. 
D: Acinar size  (µm2) of MCF-10A cells, expressing HDAC7/SA-ER, in 3D cu lture for 4, 8, and 12 days. When cells 
were seeded, 4-OHT was added to culture medium as well as every fourth day in culture.  
E: Number of nuclei per acinus, as generated by MCF-10A cells expressing HDAC7/SA-ER or the control, after 12 
days in 3D culture.  
F: Confocal images comparing the presence of picnotic fragmented apoptotic nuclei in the lumen of acini generated 
by MCF-10A cells, expressing HDAC7/SA-ER or the control, grown in 3D culture for 12 days. Nuclei were stained 
with Hoechst 33258. Images are shown in pseudocolors. 
G: Quantificat ion of number of acini with normal nuclei in the lumen, as generated by MCF-10A expressing the 
different transgenes after 12 days in 3D cu lture. 
H: Quantification of the number of apoptotic cells per acin i, as generated by MCF-10A expressing the different 
transgenes after 12 days in 3D cu lture.  
 
 
MEF2-dependent transcription and HDAC7 levels are regulated during growth arrest in 
mammary epithelial cells.  
 
The discovery that MEF2 activity influences cell cycle progression encouraged us to address 
whether this response can be observed also independently from the epithelial morphogenetic 
process. As alternative conditions for G0 induction, exit from the cell cycle was promoted by 
density dependent inhibition and by growth factors starvation. Under contact inhibition MEF2A 
and MEF2D protein levels increase in the absence of appreciable rises of the relative mRNAs 
(Fig. 6A and B). As above described for 3D culture, HDAC7 protein levels decrease and 
HDAC5 increase (Fig. 6A). Expression of KLF2, RHOB, and HDAC5 augments, whereas 
HDAC7 mRNA levels are unchanged (Fig. 6B). Similar results were obtained when G0 entering 
was elicited by serum and growth factors deprivation (Fig. 6C and D). Serum starvation 
promoted the down-regulation of HDAC4 as previously observed (Cernotta et al., 2011). 
Induction of HDAC7 repressive activity using the HDAC7/SA-ER chimera in MCF-10A cells 
subjected to growth factors deprivation limited the up-regulation of RHOB mRNA expression 
levels (Fig. 7A), sustained cell proliferation (Fig. 7B), and DNA synthesis (Fig. 7C). An increase 
in cell proliferation (Fig. 7B) and in S phase (data not shown) can also be achieved using a 
conditionally active mutant form of HDAC4. Compared to the results obtained in presence of 
epidermal growth factor (EGF) in the medium, the HDAC7/SA-ER chimera is less capable to 
repress RHOB and sustain DNA synthesis. This partial effect depends on the dramatic decrease 
in its expression observed when cells are deprived of serum and growth factors (Fig. 7D and E). 
The most prominent effect of cell cycle exit on the MEF2-HDAC axis, in both 3D and 2D 
culture models, is the down-regulation of HDAC7. To verify whether the up-regulation of 
MEF2-target genes depends on the release of a repressive influence operated by the deacetylase 
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on the promoter of such genes, we performed CHIP analysis. The RHOB promoter was selected 
as a prototype for MEF2-target gene. Figure 6E illustrates that HDAC7 binds the RHOB 
proximal promoter during the proliferative phase, whereas the binding is clearly reduced upon 
growth arrest as induced by either density dependent inhibition or serum starvation. 
 
                                          
 
Figure 6: MEF2-dependent transcription and HDAC7 levels are regulated during growth arrest in 
mammary epithelial cells. 
A: Immunoblot analysis of MEF2 family members  and class IIa HDACs levels in MCF-10A cells, seeded in 
complete medium, at the indicated time po ints. Akt was used as loading control. Cell cycle analysis is provided.  
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B: qRT-PCR was performed to quantify mRNA levels of class IIa members (HDAC4, HDAC5, and HDAC7) as 
well as of MEF2s members (MEF2A, and MEF2D) and MEF2-taget genes (KLF2, and RHOB) in MCF-10A cells. 
Fold induction was calculated as the ratio relative to 1 day of culture in complete medium.  
C: Immunoblot analysis of MEF2 family members  and class IIa HDACs levels, in MCF-10A cells cultured at 
different growing conditions. Akt was used as loading control. Cell cycle analysis is provided. 
D: qRT-PCR was performed to quantify mRNA levels of class IIa members (HDAC4, HDAC5, and HDAC7) as 
well as of MEF2s members (MEF2A, and MEF2D) and MEF2-taget genes (KLF2, and RHOB) in MCF-10A cells. 
Fold induction was calculated as the ratio relative to growing condition. 
E: qRT-PCR analysis on chromatin immunoprecipitated with the indicated antibodies in different conditions as 
showed. 
    
 
Figure 7: HDAC7 influences MEF2-dependent transcription and cell proliferation in mammary 
epithelial cells. 
A: qRT-PCR was performed to evaluate RHOB mRNA levels in MCF-10A cells expressing ER or HDAC7/SA-ER 
chimera. 
B: MCF-10A cells expressing the indicated transgenes were grown in normal medium deprivated of EGF.  
C: MCF-10A cells expressing ER or HDAC7/SA-ER chimera were seeded and after 24h  BrdU was added for 2h, 
and then cells were processed for immunofluorescence. 
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D: Immunoblot analysis of HDAC7/SA-ER in MCF-10A cells expressing HDAC7/SA-ER chimera subjected or not 
to serum and growth factors deprivation.  Actin was used as loading control. 
E: qRT-PCR was performed to evaluate HDAC7/SA-ER mRNA levels in MCF-10A cells expressing HDAC7/SA-
ER ch imera subjected or not to serum and growth factors deprivation. 
 
 
HDAC7 binds the p21 promoter. 
 
Cyclin-dependent kinases (CDKs) are master regulators of cell cycle progression and cell 
proliferation. The CDK inhibitor 1A (CDKN1A), also named p21, is a well-known negative 
regulator of proliferation, under the control of multiple signals, including growth factors and 
differentiation (Besson et al., 2008). Some reports have suggested that class IIa HDACs could be 
involved in the regulation of CDKN1A transcription (Wilson et al., 2008)(Mottet et al., 2009)(R. 
Liu et al., 2009). To explore whether MEF2 factors and class IIa HDACs control p21 expression 
during acinar morphogenesis, we initially interrogated the ENCODE database to map the 
epigenetic status of CDKN1A promoter in human mammary epithelial cells (HMEC)(Ernst et 
al., 2011)(Rosenbloom et al., 2013). We have considered the genomic region comprised between 
two insulators (CTCF).  Histone 3 lysine 4 trimethylation (H3K4me3) and histone 3 lysine 27 
acetylation (H3K27Ac), well-known markers of open chromatin status and characteristics of 
active promoter and enhancer regions, define the first intron as the important element involved in 
CDKN1A transcription (Fig. 8A). A similar pattern can be observed also in human 
lymphoblastoid GM12878 cells (Fig. 8B) and in leukemia K562 cells (data not shown). 
Interestingly available ENCODE data for GM12878 and K562 cell lines highlighted a conserved 
binding of MEF2 factors in the promoter/enhancer elements  (Fig. 8C), although with a slight 
variation in the position.  
Next we screened for potential MEF2 binding sites a 20 Kb genomic region of CDKN1A, 
comprising the first intron, containing the active chromatin markers above described. The 
enlargement in figure 8A illustrates the presence of several potential MEF2 binding sites in the 
analyzed genomic region and particularly in the first intron, where epigenetic signatures mark 
active enhancers. 
To evaluate the involvement of HDAC7 in the regulation of the CDKN1A transcription, we 
decided to investigate its ability to bind the regions highlighted in figure 8A. CHIP experiments 
proved that HDAC7 binds preferentially the region containing the MEF2 binding site at +1.5 Kb 
from the transcription start site. Importantly, this binding is abolished or dramatically reduced 
when growth arrest was induced by growth factor starvation or high confluence (Fig. 9A).  
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The involvement of the MEF2-HDAC axis in the regulation of CDKN1A transcription was 
confirmed after induction of the MEF2-VP16-ER chimera in 2D conditions (Fig. 9B and C) and 
by the repression operated by the HDAC7/SA-ER chimera in 3D conditions (Fig. 9D). 
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Figura 8: Epigenetic status of p21 promoter. 
A: Schemat ic representation of the epigenetic status of the CDKN1A locus in human mammary ep ithelial cells , as 
mapped with the ENCODE project. The analyzed region was comprised within two insulator CTCF peaks and the 
promoter has been identified through H3K4me3 and H3K27Ac signals. A region of 20 Kb, highlighted in the black 
box, including the promoter, has been selected and scanned for putativeMEF2 binding sites. 
B: Schemat ic representation of the epigenetic status of the CDKN1A locus in human lymphoblastoid GM12878 
cells, as mapped with the ENCODE pro ject. The analyzed region was comprised with in two insulator CTCF peaks 
and the promoter has been identified through H3K4me3 and H3K27Ac signals. Arrows mark M EF2 b inding sites 
identified by ECODE consortium.  
C: Schematic representation of the MEF2A and MEF2C peaks in the CDKN1A locus in human lymphoblastoid 
GM12878 cells, as mapped with the ENCODE project. MEF2 factors associate with regions marking both promoter 
(H3K4me3) and enhancer (H3K4me1) elements. 
 
 
 
                           
 
Figure 9: HDAC7 binds the p21 promoter. 
A: qRT-PCR analysis on chromatin immunoprecipitated with the indicated antibodies in different conditions as 
showed. The different genomic reg ions of CDKN1A, containing putative MEF2 binding sites, are indicated starting 
from the transcription start site. An internal reg ion (+4.7 Kb) of the CDKN1A gene was used as a negative control.  
B: qRT-PCR was performed to quantify CDKN1A mRNA levels in  cells in which MEF2-transcription was induced 
after treatment with 4-OHT. Fold induction was calculated as the ratio relative to cells in  which the expression of 
MEF2 defect ive in DNA binding was induced by 4-OHT treatment as indicated.  
C: Immunoblot analysis of MCF-10A cells expressing the indicated transgene and analysed for p21/CDKN1A 
levels. Induction of the transgenes was performed as in C.  
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D: mRNA expression levels of CDKN1A were measured by using qRT-PCR in MCF-10A cells expressing 
HDAC7/SA-ER or control grown in 3D culture for 8 days. 4-OHT was added to culture medium the day of seeding 
and the fourth day of culture.  
 
 
The MEF2-HDAC axis is regulated during HER2-mediated transformation of mammary 
epithelial cells. 
 
The contribution of the MEF2-HDAC axis to the regulation of mammary epithelial cells 
proliferation prompted us to determine whether oncogenic lesions, altering mammary epithelial 
morphogenesis, can provoke dysregulation of the MEF2-HDAC axis. The tyrosine kinase 
receptor HER2 (human epidermal growth factor receptor 2) is the key determinant of a subclass 
of breast tumors and its overexpression profoundly alters normal mammary epithelial 
morphogenetic process (Leung and Brugge, 2012). Hence, we generated MCF-10A cells 
overexpressing HER2 to assess dysregulations of the MEF2-HDAC axis. After 16 days in 3D 
culture, HER2 overexpressing cells showed an elevated proliferative index as proved by the 
development of larger acini (Fig. 10A), composed by higher numbers of cells per structure and 
marked by the presence of mitotic figures even at day 16 (Fig. 10B). Moreover the compromised 
epithelial organization is manifested by alterations in polarity and the presence of cells in the 
luminal cavity (Fig. 10B). Accordingly, HER2 significantly reduced the expression of the 
epithelial morphogenesis markers (BIM and BMF). Similarly, also the mRNA levels of certain 
MEF2-target genes (KLF2, RHOB, and CDKN1A) are reduced (Fig. 10C). Importantly, the 
decrease in MEF2-dependent transcription is coupled to the rescue of HDAC7 protein levels at 
day 16 (Fig. 10D). Curiously, MEF2D protein levels seem to be increased in HER2 expressing 
cells. Conversely, the inhibition of HER2 tyrosine kinase activity with lapatinib dramatically 
impacts on epithelial growth, thus limiting acinar size (Fig. 10E). The number of cells per 
structure and mitotic figures were also reduced in lapatinib treated cells (Fig. 10F). Lapatinib 
also restored the appearance of acini with hollow lumen (Fig. 10F). Interestingly, the effect of 
this inhibitor seems to be cell cycle preponderant, without interferences with the induction of 
apoptosis, as testified by the unchanged rate of p icnotic and fragmented nuclei per acini (Fig. 
10F).  
In agreement with our studies, treatment of MCF-10A cells expressing HER2, grown for 16 days 
in 3D culture with lapatinib, up-regulated MEF2-dependent transcription, the expression of BIM 
and BMF morphogenetic markers (Fig. 10G), and elicited the down-regulation of HDAC7 (Fig. 
10H). Interestingly also HDAC4 protein levels seem to be reduced after HER2 inhibition.  
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Importantly, induction of MEF2 transcription in MCF-10A cells expressing HER2 restores 
normal epithelial morphogenesis similarly to lapatinib. All the proliferative parameters (average 
nuclei/acinus, percentage of acini with mitotic figures and of acini with normal nuclei in the 
lumen) were reduced following MEF2 activation in HER2-overexpressing cells (Fig. 10I).  
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Figure 10: The MEF2-HDAC axis is regulated during HER2-mediated transformation of 
mammary epithelial cells. 
A: Acinar size (µm2) of MCF-10A cells expressing HER2 in 3D culture for 16 days. 
B: Number of nuclei per acinus, number of acini with normal nuclei in the lumen, number of acini with mitotic 
figures and number of polarized acin i, as generated by MCF-10A cells expressing HER2, after 16 days in 3D 
culture. 
C: qRT-PCR was performed to evaluate mRNA levels of MEF2-target genes in MCF-10A cells expressing HER2 
cultured in 3D for 16 days.  
D: Immunoblot analysis of MEF2 family members and class IIa HDACs levels in MCF-10A cells expressing HER2 
grown in 3D for 16 days. Akt was used as loading control.  
E: Acinar size  (µm2) of MCF-10A cells expressing HER2 in 3D culture for 16 days and treated or not with lapatin ib. 
F: Number of nuclei per acinus, number of acini with normal nuclei in the lumen, number of acini with picnotic and 
fragmented apoptotic nuclei and number of acini with mitotic figures, as generated by MCF-10A cells expressing 
HER2 treated or not with lapatinib, after 16 days in 3D culture.  
G: qRT-PCR was performed to evaluate mRNA levels of MEF2-target genes in MCF-10A cells expressing HER2 
treated or not with lapatin ib cultured in 3D for 16 days.  
H: Immunoblot analysis of MEF2 family members and class IIa HDACs levels in MCF-10A cells expressing HER2, 
treated or not with lapatin ib, grown in 3D for 16 days. Total ERK was used as loading control.  
I: Number o f nuclei per acinus, number o f acini with picnotic and fragmented apoptotic nuclei, number of acin i with 
mitotic figures and number of acini with normal nuclei in the lumen, as generated by MCF-10A cells expressing 
HER2-MEF2-VP16-ER chimera or its mutant defective in DNA binding MEF2-ΔDBD-VP16-ER, after 8 days in 
3D culture. MEF2-VP16-ER-activation was induced by adding to growth medium 4-OHT after 4 days in 3D culture.  
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The mammary gland undergoes a complex remodeling during different phases like puberty, 
pregnancy, lactation, and involution (Gjorevski and Nelson, 2011). 3D cultures have become an 
important and attractive model for studying and understanding how some of these processes take 
place. Human mammary epithelial cells (MCF-10A) grown under 3D conditions develop 
structures that resemble the organization of epithelial cells within the terminal ductal lobular 
units (Schmeichel and Bissell, 2003). Although it is a simple model for epithelial 
morphogenesis, complex cellular decisions occur during the 16 days interval, necessary for acini 
formation. After the initial proliferation phase, cells begin to polarize and gradually exit from the 
cell cycle. The process terminates with the death of the cells in the lumen and cavity formation. 
This model, although does not induce terminal differentiation and milk protein production, 
imposes a 3D environment that influences cell behavior and mimics steps required for a proper 
developmental and homeostatic cue (Lo et al., 2012)(Shaw et al., 2004)(Leung and Brugge, 
2012).   
In this context we have studied the regulation of MEF2-HDAC axis and dissected its 
contribution to the epithelial morphogenetic program. Previous works have demonstrated that 
quantitative and qualitative changes in gene expression profiles characterize the morphogenetic 
process of MCF-10A cells grown under 3D condition (Yu et al., 2012). However, few studies 
have addressed the contribution of specific transcriptional factors and of the relative gene 
networks to this morphogenetic process. We have initially demonstrated that expression of 
MEF2-target genes is augmented during MCF-10A acini formation. This behavior resembles 
other differentiation contexts, such as skeletal muscle, where the contribution of the axis was 
previously studied (T A McKinsey et al., 2000)(Sebastian et al., 2013). Activation of MEF2-
dependent transcription is coupled to a dramatic down-regulation of HDAC7 protein levels. In 
MCF-10A cells, differently from other cellular models, anti-proliferative signals unleash MEF2-
dependent transcription, by impacting on HDAC7 levels, rather than by controlling nucleo-
cytoplasmic shuttling of class IIa HDACs (T A McKinsey et al., 2000)(Paroni et al., 2008). We 
noticed that HDAC7 down-regulation is linked to cell growth arrest and it can be observed also 
in 2D culture condition, after growth factors starvation or density dependent inhibition. However 
at the moment the mechanism responsible for HDAC7 down-regulation is unknown. We can 
only exclude changes in mRNA levels, in proteasomal degradation or in autophagy.   
Interestingly, HDAC5 and HDAC9 expression increases during acini formation. Being both 
MEF2-target genes, it is possible that such induction is part of the well-known negative feed-
back loop activated by MEF2 itself (Haberland et al., 2007). Nevertheless, since HDAC7 is the 
highest expressed class IIa deacetylase in breast tissue and in MCF-10A cells, its withdrawal 
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justifies the up-regulation of MEF2-dependent transcription. Furthermore, some reports indicate 
a differential repressive capability of class IIa HDACs towards MEF2 factors with HDAC5 
being the less prone enzyme (Lemercier et al., 2000). 
We exploited different approaches to interfere with the MEF2 transcriptional activity. The down-
regulation of MEF2D did not show any evident cellular changes/phenotypes. This failure can be 
explained with the presence of MEF2s compensatory mechanisms. This behavior was also 
observed and reported in other contexts (N. Liu et al., 2014). By contrast increasing MEF2-
dependent transcription or boosting HDAC7-repressive activity has an effect on the proliferative 
phase of the morphogenic process, reducing cell division or favoring cell proliferation, 
respectively. However, in both cases, important steps that lead to acini formation, such as 
polarization and induction of cell death, were unaffected after modulation of the MEF2-HDAC 
axis. 
In this work we proposed that the influence of the MEF2-HDAC axis on cell proliferation could 
be operated through the regulation of CDK inhibitor 1A (CDKN1A/p21). Previous works have 
shown that class IIa HDACs can control CDKN1A expression (Wilson et al., 2008)(Mottet et al., 
2009)(R. Liu et al., 2009), however the mechanisms involved are debated. MEF2 binding sites 
are present in the genomic region embracing CDKN1A. In particular several of them lie within 
the first intron in correspondence of markers of open chromatin conformation (Ernst et al., 
2011). Our results suggest that the MEF2-HDAC axis imposes a control on cell cycle by 
modulating CDKN1A expression through the recruitment of HDAC7 at position +1.5 Kb from 
the transcription start site, where a MEF2 binding site is located. HDAC7 binding is dramatically 
reduced under conditions stimulating cell cycle arrest. Although class IIa HDACs do not 
manifest catalytic activity, they can act as platforms beckoning class I enzymes (Lahm et al., 
2007)(Di Giorgio et al., 2014). Interestingly the recruitment of HDAC7 on p21 promoter is 
confined in a region identified under the control of MEF2 factors also by ENCODE, in other 
different cell lineages.  
Finally we decided to study the effect of the alteration of MEF2-HDAC axis on mammary 
epithelial cells proliferation, inducing HER2 overexpression, a frequent oncogenic event in 
breast tumor. HER2 is able to maintain HDAC7 levels and decrease MEF2-dependent 
transcription, compromising all the parameters/steps that are important for mammary epithelial 
organization. Interestingly forcing MEF2 activity in MCF-10A cells overexpressing HER2 
reverts the transformed phenotype mainly by restraining proliferation, thus ensuring a correct 
epithelial organization. Furthermore treatment with the receptor tyrosine kinase inhibitor 
lapatinib rescued HDAC7 down-regulation and acini formation in 3D culture cells. 
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In conclusion our studies unveil a role of the MEF2-HDAC axis in the control of epithelial cells 
proliferation and suggest that class IIa HDACs specific inhibitors could be an interesting 
therapeutic strategy in addition to or in combination with RTK inhibitors for the treatment of 
breast cancer.  
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MEF2 Is a Converging Hub for Histone Deacetylase 4 and
Phosphatidylinositol 3-Kinase/Akt-Induced Transformation
Eros Di Giorgio,a Andrea Clocchiatti,a Sara Piccinin,b Andrea Sgorbissa,a Giulia Viviani,a Paolo Peruzzo,a Salvatore Romeo,c
Sabrina Rossi,c Angelo Paolo Dei Tos,c Roberta Maestro,b Claudio Brancolinia
Dipartimento di Scienze Mediche e Biologiche, Università degli Studi di Udine, Udine, Italya; Experimental Oncology 1, CRO National Cancer Institute, Aviano, Italyb;
Department of Anatomical Pathology, Treviso General Hospital, Treviso, Italyc
The MEF2-class IIa histone deacetylase (HDAC) axis operates in several differentiation pathways and in numerous adap-
tive responses. We show here that nuclear active HDAC4 and HDAC7 display transforming capability. HDAC4 oncogenic
potential depends on the repression of a limited set of genes, most of which are MEF2 targets. Genes verified as targets of
the MEF2-HDAC axis are also under the influence of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway that affects
MEF2 protein stability. A signature of MEF2 target genes identified by this study is recurrently repressed in soft tissue sar-
comas. Correlation studies depicted two distinct groups of soft tissue sarcomas: one in which MEF2 repression correlates
with PTEN downregulation and a second group in which MEF2 repression correlates with HDAC4 levels. Finally, simulta-
neous pharmacological inhibition of the PI3K/Akt pathway and of MEF2-HDAC interaction shows additive effects on the
transcription of MEF2 target genes and on sarcoma cells proliferation. Overall, our work pinpoints an important role of
the MEF2-HDAC class IIa axis in tumorigenesis.
Gene transcription is under the influence of complex regulativenetworks integrating multiple signaling events that end up
with the final decision of activating or repressing specific genetic
programs. Histone deacetylases (HDACs) play important roles in
the regulation of different genetic programs controlling differen-
tiation, survival, tissue homeostasis and metabolism (1, 2).
Among the different deacetylases, the class IIa HDACs, including
HDAC4, HDAC5, HDAC7, and HDAC9, show a limited enzy-
matic activity but are equally powerful repressors of transcription
by virtue of assembly into multiprotein complexes that recruit
other transcriptional corepressor (3–5). Environmental signals
control class IIa HDACs activities through different strategies, in-
cluding regulation of transcription/translation, ubiquitin-depen-
dent degradation, and selective proteolysis (6–11).
A widespread and rapid strategy to modulate class IIa repres-
sive potential is operated through the control of their subcellular
localization. These deacetylases shuttle in and out of the nucleus in
a phosphorylation-dependentmanner. A set of conserved serines,
once phosphorylated become docking sites for 14-3-3 chaperone
proteins, which escort the deacetylases from the nucleus into the
cytoplasm, thus limiting their repressive influence (1, 5, 11–13). In
contrast, phosphatases such as PP2A can promote HDAC nuclear
import and consequently gene repression (14, 15).
Since class IIa HDACs omit DNA-binding domains, theymust
bind DNA-binding transcription factors in order to influence
gene expression (1, 5, 16–18). Important partners of class IIa
HDACs are the transcription factors of the MEF2 family. Genetic
studies and the generation of animal models testified to the im-
portant role of theMEF2-HDAC axis during development, differ-
entiation, and tissue homeostasis (19).
Molecular pathways that normally ensure proper embryogen-
esis and tissue maintenance in postembryonic life are subverted
during the carcinogenetic process (20). Alterations of the class IIa
HDACs and MEF2 transcription factors have been observed in
certain cancers (11, 21–24). Overall, the data are scattered and
debated, and, more importantly, the impact of the MEF2-
HDAC axis on the tumorigenic process is still undefined. In the
present study we addressed the prooncogenic role for class IIa
HDACs. Since previous reports correlated HDAC4 with cell
proliferation (25–27), we focused in particular on this deacety-
lase as a model.
MATERIALS AND METHODS
Cell cultures and reagents. NIH 3T3 mouse fibroblasts and human
IMR90-E1A cells were grown in Dulbecco modified Eagle medium
(DMEM; Lonza) supplemented with 10% fetal bovine serum (FBS), L-
glutamine (2 mM), penicillin (100 U/ml), and streptomycin (100 g/ml)
(all fromLonza). Cells expressing the inducible formofMEF2were grown
in DMEM without phenol (Sigma-Aldrich). BALB/c 3T3 cells were gen-
erated from BALB/c primary MEF using the 3T3 protocol (28) and were
grown in DMEM supplemented with 10% calf serum. The human leio-
myosarcoma cell lines SKUT-1, DMR, and SK-LMS1 were cultivated as
previously described (42). For analyses of cell growth, 104 cells were
seeded, and the medium was changed every 2 days.
The following chemicals were used (the final concentrations are indi-
cated): 20 M LY (LY294002; LC laboratories); 2.5 M MG132, 10 M
BML-210, 1M4-hydroxytamoxifen (4-OHT), 10M resazurin, 0.5 mg
ofMTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazoliumbro-
mide]/ml, and dimethyl sulfoxide (DMSO) (all from Sigma-Aldrich); and
leptomycin B (LC Laboratories). The primary antibodies were anti-green
fluorescent protein (anti-GFP), anti-HDAC4 (29), antipaxillin, and anti-
Ran (BD Transduction Laboratories), anti-VP16 (sc-7545; Santa Cruz),
antihemagglutinin (anti-HA; Sigma-Aldrich), antiubiquitin (Cova-
nce), anti-nucleoporin p62, anti-RAN, anti-pp120, and anti-MEF2D
Received 13 August 2013 Accepted 9 September 2013
Published ahead of print 16 September 2013
Address correspondence to Claudio Brancolini, claudio.brancolini@uniud.it.
Supplemental material for this article may be found at http://dx.doi.org/10.1128
/MCB.01050-13.
Copyright © 2013, American Society for Microbiology. All Rights Reserved.
doi:10.1128/MCB.01050-13
November 2013 Volume 33 Number 22 Molecular and Cellular Biology p. 4473–4491 mcb.asm.org 4473
Di Giorgio et al.
4474 mcb.asm.org Molecular and Cellular Biology
(BD Transduction Laboratories), and anti-Erk, ant-pErk, anti-Akt,
anti-Aktp473, anti-MEF2C D80C, and anti-MYC (Cell Signaling).
Plasmid construction, transfection, retroviral infection, and silenc-
ing. pEGFPN1 constructs expressing human HDAC4 and its mutants,
pcDNA3.1 HA-MEF2C, 3MEF2-Luc, and pRL-CMV, were previously
described (9). All of the cDNAs used were from humans. Cells expressing
the different transgenes were generated by retroviral infection as de-
scribed previously (9). To generate pBABE-Puro-MEF2c-VP16-ER,
p-BABE-MEF2cDBD-VP16-ER, pWZL-Hygro-MEF2c-VP16-ER, and
pWZL-Hygro-MEF2c-DBD-VP16-ER MEF2, the relative cDNAs were
subcloned into pBABE-Puro and pWZL-Hygro plasmids using a PCR
method and then checked by sequencing. The dominant-negative version
of MEF2 encodes for amino acids (aa) 1 to 117. pWZL-HDAC4-
TMMEF2was generated in two steps. TheN terminus (aa 1 to 166 and aa
184 to 221) was generated by PCR and cloned into pcDNA3 (EcoRI/
BamHI and BamHI/SalI). Finally, fragment 1-221 was subcloned into
pWZL-HDAC4-TM-GFP restricted by using Eco-SalI. Silencing of NIH
3T3 and IMR90-E1A were performed with 70 M small interfering RNA
(siRNA; Invitrogen).
Immunofluorescence and immunoblotting.Cellswere fixedwith 3%
paraformaldehyde and permeabilized with 0.1% Triton X-100. The sec-
ondary antibodies were Alexa Fluor 488-, 546-, or 633-conjugated anti-
mouse and anti-rabbit secondary antibodies (Molecular Probes). Actin
was labeled with phalloidin-AF546 (Molecular Probes) or phalloidin-
ATTO 665 (Sigma-Aldrich). The cells were imaged with a Leica confocal
scanner SP equipped with a 488  Ar laser and a 543 to 633 HeNe laser.
Cell lysates after SDS-PAGE and immunoblottingwere incubatedwith
primary antibodies. Secondary antibodies were obtained from Sigma-
Aldrich, and blots were developed with Super Signal West Dura (Pierce).
For antibody stripping, blots were incubated for 30 min at 60°C in strip-
ping solution containing 100 mM -mercaptoethanol.
RNA extraction and quantitative qRT-PCR. Cells were lysed using
Tri-Reagent (Molecular Research Center). A total of 1 g of total RNA
was retrotranscribed by using 100 U of Moloney murine leukemia virus
reverse transcriptase (Invitrogen). Quantitative reverse transcription-
PCR (qRT-PCR) analyses were performed using Bio-Rad CFX96 and
SYBR Green technology. The data were analyzed by use of a comparative
threshold cycle using 2-microglobulin, HPRT (hypoxanthine phospho-
ribosyltransferase), and -actin as normalizer genes. All reactions were
done in triplicate.
Adhesion and random motility measurements. Random motility
was assayed by time-lapse video microscopy as previously described (9).
To study adhesion and spreading, plates were coated with 10 g of fi-
bronectin/ml or bovine serum albumin (BSA; Sigma-Aldrich). Cells were
seeded at 6 104/ml and, after 10min, time-lapse analysis was performed.
Time-lapse images were analyzed by using Metamorph software (Molec-
ular Devices) and ImageJ. The results are pooled from eight independent
experiments.
Soft agar and tumorigenicity assays. Equal volumes of 1.2% agar and
DMEM were mixed to generate 0.6% base agar. A total of 105 NIH 3T3,
BALB/c 3T3, or sarcoma cells expressing the different transgenes were
seeded in 0.3% top agar, followed by incubation at 37°C in humidified
conditions. The cells were grown for 15 days, and the culturemediumwas
changed twice per week. Foci were visualized by using MTT staining. For
tumorigenicity assays, 400,000 cells expressing the different transgenes
were injected subcutaneously into immunocompromised nude mice. In
parallel, 100,000 cells of the same cell suspension were plate counted 24 h
after plating to check for equal number injection and cell viability. The
tumor size was monitored twice per week.
RNA expression array and data analysis. Total RNA was isolated by
using RNeasy (Qiagen). RNA samples were labeled according to the stan-
dard one-cycle amplification and labeling protocol (Affymetrix, Santa
Clara, CA). Labeled cRNAs were hybridized on Affymetrix GeneChip
Gene 1.0 ST mouse arrays. Scanning was performed using a GeneChip
Scanner 3000 7G (Affymetrix), whereas Microarray Analysis Suite 5.0
software (Affymetrix) was used for preliminary data analysis. One-way
analysis of variance was applied to replicates to discard missense gene
expression values.We adopted a cutoff of 1.5 for the fold change. Gene set
enrichment analysis (GSEA) (30) was used to investigate putative statis-
tical association between genes modulated by HDAC4 and genes per-
turbed by other signal transduction pathways. The HDAC4 signature was
used to interrogate 3,272 curatedMSigDB gene sets and 91 data sets avail-
able on the GEO database (http://www.ncbi.nlm.nih.gov/geo/) and com-
ing from DNA microarray experiment on murine fibroblasts. For the
analysis, the maximum value of each probe was chosen; the ranking was
done according to a signal-to-noise metric, and 1,000 permutations were
used to generate the null distribution.
HDAC assay. HDAC assay was performed using a fluorogenic assay
kit, the Fluor de Lys-Green HDAC assay (BIOMOL), according to man-
ufacturer’s instructions. Briefly, HDAC4 immunoprecipitates were resus-
pended in the HDAC assay buffer and incubated with Fluor de Lys-Green
substrate for 30 min at 37°C. The fluorogenic reaction was triggered by
adding developer according to the manufacturer’s instructions, and the
fluorescence was measured after 15 min and stopped with trichostatin A
(TSA). HDAC inhibitor TSA (40 M) was used as an internal control to
measure the background signal. A total of 1.5 g of anti-HDAC4 and
anti-USP33, as a control IgG, were used for immunoprecipitations.
Chromatin immunoprecipitation. For each chromatin immunopre-
cipitation, 4.5 106 cells were used. DNA-protein complexes were cross-
linked with 1% formaldehyde (Sigma-Aldrich) in phosphate-buffered sa-
line (PBS) for 15 min at room temperature. After quenching and two
washes in PBS, the cells were collected and then lysed for 10min with lysis
buffer (5 mM PIPES, 85 mM KCl, 0.5% NP-40) containing protease in-
hibitor cocktail (Sigma-Aldrich). The pellets were resuspended in RIPA-
100 and sonicated using a BioruptorUCD-200 (Diagenode)with pulses of
30 s for 15 min, resulting in an average size of500 bp for genomic DNA
fragments. Samples were precleared and immunoprecipitated overnight
with 2 g of anti-GFP or anti-USP33 antibodies, followed by incubation
with proteinA blockedwith BSA and salmon spermDNA (1g/l) at 4°C
for 2 h. Beads and inputs were treated with proteinase K overnight at 68°C
to degrade proteins and reverse cross-linking. Genomic DNA was finally
purifiedwithQiagenQIAquick PCRpurification kit and eluted in 65l of
water.
FIG 1 Morphological changes in cells expressing HDAC4/TM. (A) Confocal pictures of NIH 3T3 cells expressing GFP and the different chimeras. Immuno-
fluorescence analysis was performed to visualize HRasV12. AF546-phalloidin was used to decorate F-actin. Scale bar, 50 m. (B) Immunoblot assays were
performed to visualize the different transgenes. The antibodies used were anti-GFP to detect GFP and HDAC4-GFP, anti-HRas, and anti-Erks as a loading
control. (C) qRT-PCRanalysis was performed to quantifymRNAs levels of theHDAC4-target gene,Klf2. Gapdhwas used as a control gene. TheKlf2mRNA levels
were relative to GFP-expressing cells. (D) Confocal pictures of cells expressing GFP, GFP-HDAC4/WT, and GFP-HDAC4/TMi2. Immunofluorescence analysis
was performed to visualize paxillin subcellular localization. AF546-phalloidin was used to decorate F-actin. Scale bar, 50 m. (E) NIH 3T3 cells expressing
HDAC4/WT, HDAC4/TMi2, or GFP were plated onto BSA- or fibronectin-covered dishes and subjected to time-lapse analysis for the indicated times. The data
are presented as the average areas. (F) At 24 h after seeding, NIH 3T3 cells expressing HDAC4/WT, HDAC4/TMi2, or GFP were subjected to time-lapse analysis
for 6 h. The data are presented as the average migration rates. (G) qRT-PCR analysis was performed to quantify Klf2 mRNAs after the transfection of cells
expressing HDAC4/TMi2 with siRNA against HDAC4 or control siRNA. Klf2 mRNA levels were relative to GFP-expressing cells. Immunoblotting was per-
formedwith anti-GFP antibodies to prove the siRNA efficiency. (H)Confocal pictures of cells expressingHDAC4/TMi2 transfectedwith siRNAs againstHDAC4
or control siRNA. Immunofluorescence analysis was performed as described in panel D. Scale bar, 50 m. *, P 0.05; ***, P 0.001.
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FIG 2 Transforming ability of HDAC4/TM. (A) NIH 3T3 cells expressing the indicated transgenes were grown in DMEM supplemented with 10% FBS. (B)
Growth in soft agar of NIH 3T3 expressing the indicated transgenes, foci were stained with MTT. (C) Quantitative results of colony formation. (D) Analysis of
the tumorigenic properties of NIH 3T3 cells expressing the indicated genes when injected into immunocompromised nude mice. HDAC4/TM-expressing cells
generate tumors, with nodules becoming palpable20 days later compared to HRasV12-transformed cells. Pictures were obtained at week 6. (E) Immunoblot
assays were performed to visualize the different transgenes expressed in the BALB/c 3T3 cell lines. The antibodies used were anti-GFP to detect GFP and
HDAC4-GFP. Anti-Erks antibody was used as a loading control. (F) Quantitative results of colony formation in soft agar of BALB/c cells expressing the indicated
transgenes. (G) Analysis of the tumorigenic properties of BALB/c 3T3 cells expressing the indicated genes when injected into immunocompromised nude mice.
(H) Confocal pictures of NIH 3T3 cells expressing GFP chimeras of HDAC7-WT and a mutant defective in the four serine binding sites for 14-3-3 proteins
(HDAC7-S/A). Scale bar, 50m. (I) Immunoblot assays were performed to visualize the different transgenes expressed in the NIH 3T3 cell lines. The antibodies
used were anti-GFP to detect GFP, HDAC7-WT, and HDAC7-S/A. Anti-p62 antibody was used as a loading control. (J) qRT-PCR analysis was performed to
quantify mRNAs levels of Klf2. Gapdh was used as control gene. Klf2 mRNA levels were relative to GFP-expressing cells. (K) Quantitative results of colony
formation in soft agar of NIH 3T3 cells expressing the indicated transgenes. **, P 0.01; ***, P 0.001.
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FIG 3 Identification of genes repressed by HDAC4/TM. (A) Diagram representation of the HDAC4/TM target genes. Microarray analyses were performed on
GFP- and HDAC4/TM-expressing cells (repressed genes are indicated in red) and in HDAC4/TM cells transfected with control siRNA and the same cells
transfected with a siRNA against human HDAC4 (induced genes are indicated in green). (B) Gene ontology (GO) analysis using the PANTHER database was
performed to interpret the biological processes under the regulation of the 47 genes repressed by HDAC4. (C) GO analysis using the PANTHER database was
performed to classify the 47 genes repressed byHDAC4 in terms of subcellular localization. (D toG)GSEAplots show the enrichment ofHDAC4-repressed genes
among protein coding genes ranked according to PTEN and TSC2 status and the fold change in LY-treated cells versus control cells. See Materials andMethods
for details.
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Reporter gene assay.The promoter ofRhoB (300 bp)was cloned from
NIH 3T3 genomic DNA by PCR into the pGL3 plasmid. The following
oligonucleotides were used: RhoB_FW_XhoI, 5=-ATC CTC GAG CAA
TCG GAG CCA AGC TCC GC-3=; and RhoB_RV_HindIII, 5=-ATC AAG
CTT GAG CTG GCC GGG CGC GGG CA-3=. IMR90-E1A cells were
transfected at 30 to 40% confluence with the indicated mammalian ex-
pression plasmids. In the LY experiments, cells were collected 12 h after
transfection, split into two plates, and treated after 6 h with LY-294002 or
DMSO. The luciferase activity was measured and normalized for Renilla
luciferase activity using the dual-luciferase reporter assay system accord-
ing to the vendor’s instructions (Promega). The empty vectors pEGFP or
pUSE were used to normalize the total amounts of transfected DNA.
Immunoprecipitation. Coimmunoprecipitations were performed as
previously described (9). Briefly, cells were collected directly from culture
dishes into radioimmunoprecipitation assay buffer (50mMTris-HCl [pH
8], 150mMNaCl, 0.2% SDS, 1%NP-40, 0.5% sodium deoxycholate) and
supplemented with protease inhibitors. Lysates were incubated for 5 h
with the antibody against green fluorescent protein (GFP). After 1 h of
incubation with protein A-beads (GE), several washes were performed.
Samples were resolved by SDS-PAGE and analyzed by immunoblotting.
Bioinformatics analysis. To analyze MEF2 target gene expression in
human cancers, the presence of a putative MEF2 binding site in the
proximal promoters was scored using Cister (zlab.bu.edu/mfrith
/cister.shtml). Among our list of 29 human MEF2 target genes, we
selected 25 that have good-quality probes and a proximal MEF2 bind-
ing site. For this analysis, 40 human cancer data sets available on GEO
were selected according to sample abundance and the platform used
(Affymetrix Human Genome U95 version 2 array; Affymetrix Human
Genome U133B/Plus2). The data from each DNA microarray experi-
ment were considered separately and were log2 transformed, normal-
ized at the probe set level, and median centered. In the case of multiple
probe sets, we discarded any that could hybridize with other tran-
scripts, in addition to the expected level for 	33% of the probes
(scored using PLANdbAffy [http://affymetrix2.bioinf.fbb.msu.ru]
[31] and Genecruiser [http://genecruiser.broadinstitute.org]). In the
case of missing information about a probe set, we used the class A
probe set according to the NetAffy (www.affymetrix.com/analysis
/index.affx) classification. We then collapsed the multiple values of
each gene by averaging them.
The median values representing this signature in each sample were
plotted, resulting in a series of box plots. The significance was calculated
considering as positive events the samples in which the median of the 25
MEF2 genes is less than zero and applying a Poisson test of significance.
The resulting P value was corrected for multiple testing by applying
Holm-Bonferroni correction (P  0.05). For correlation analysis, the
Spearman rank correlation coefficient and the corresponding statistical
significance were calculated using the R package.
Tissue array construction and immunohistochemistry. Paraffin-
embedded samples from leiomyosarcomawere available from26 patients.
All cases were histologically and immunohistochemically validated. Mul-
tiple tissue cores (three per sample)with a diameter of 1mmwere taken by
using a Tissue Arrayer (TMA Master 3dHistech) and arrayed on a recip-
ient block according to standard procedures. Immunohistochemistry for
HDAC4 (1:100) was performed by using an automated immunostainer
(Autostainer; Dako Cytomation). Antigen retrieval was performed with
citrate buffer at pH 6 for HDAC4 and at pH 9 with EnVision FLEX target
retrieval solution (Dako Cytomation), respectively. As a negative control,
sections were stained without adding the primary antibody. Slides were
independently evaluated by two observers. All tumors were scored for the
intensity of signal (scoring range: 0
no expression; 1
weak expression;
2 
 moderate expression; 3 
 strong expression). The presence of sub-
cellular localization (i.e., nuclear or cytoplasmic) was recorded as well.
Mean intensities and percentages of duplicate cores were used for the final
analysis.
Statistics. For experimental data, a Student t test was used. AP value of
0.05 was chosen as the statistical limit of significance. Unless otherwise
indicated, all of the data in the figures are arithmetic means  the stan-
dard deviations from at least three independent experiments.
RESULTS
Nucleus-localized HDAC4 triggers morphological changes and
increased proliferation in NIH 3T3 cells. To investigate the role
of HDAC4 in the control of cell growth and proliferation, we
engineered NIH 3T3 cells to express GFP-tagged HDAC4/WT or
its nucleus-localized version (TM), which is defective in 14-3-3
binding. This mutant, by mimicking the dephosphorylated form
(Ser/Ala mutations) of the deacetylase, displays nuclear localiza-
tion and exhibits increased repressive transcriptional activity (12,
13). NIH 3T3 cells expressing oncogenic HRasV12 or GFP were
used as positive and negative controls, respectively. Two inde-
pendent infections with the TM allele were exploited (TM/i1
and TM/i2).
Immunofluorescence analysis proved that HDAC4/WT is
mainly cytosolic (Fig. 1A) and subjected to nuclear/cytoplasmic
shuttling (data not shown). In contrast, the TM mutant is pre-
dominantly nuclear, with some cells showing pan/cytoplasmic lo-
calization. Figure 1B illustrates the expression levels of the differ-
ent transgenes. In general HDAC4/TM was expressed to less
extent compared to the WT.
The repressive influence of HDAC4 was then measured by us-
ing an MEF2 target, the transcription factor Klf2 (24) (Fig. 1C).
qRT-PCR experiments demonstrated that in HDAC4 expressing
cells Klf2 mRNA is reduced and, as expected, the TM mutant is a
more potent repressor. Klf2 mRNA levels were also decreased in
cells expressing HRasV12.
Morphological inspection of engineered cells revealed that
whereas no relevant changes in cell shape were detectable after
ectopic expression of the WT allele, the expression of the nu-
clear allele (both TM/i1 and TM/i2) resulted in the gain of a
spindle-like morphology, characterized by reduced size and
reduced spreading/adhesion (Fig. 1A and D). Moreover, the
nuclear allele promoted an overt reorganization of actin cyto-
skeleton characterized by the loss of stress fibers and by an
increase in membrane ruffles.
To gain more insight into the morphological changes induced
by HDAC4/TM we compared the organization of focal adhesions
(FA) in the different cell lines. SinceTMi1 andTMi2 evidenced the
samemorphological changes but TMi2 expressed a higher level of
FIG 4 Several HDAC4-repressed genes are MEF2 targets. (A) The mRNA expression levels for 11 HDAC4 target genes and Gapdh, as a control, were measured
using qRT-PCR in GFP- and HDAC4/TM-expressing cells. Cells were also treated with LY for 12 or 24 h. The mRNA levels were relative to untreated
GFP-expressing cells. (B) The mRNA expression levels of 11 HDAC4 target genes were measured using qRT-PCR in GFP- and MEF2DN-expressing cells. (C)
Chromatin immunoprecipitation of NIH 3T3 cells overexpressingMEF2-GFP or control Puro. Chromatin was immunoprecipitated with anti-GFP antibody or
anti-USP33 (2 g) as a control. For each of the genes examined, we compared the fold enrichment over input (1/100) between the proximal (1 to 1,000 bp) and
the distal (	3,000 bp) promoters, as indicated. (D) Nucleotide sequence analysis of the human and mouse RhoB proximal promoters. The putative MEF2
binding site is underlined. (E)Relative luciferase activity after cotransfection in IMR90-E1A cells of the reporter plasmids pRhoB-Luc (300/1) andp3MEF2-
luc, together withMEF2C, as indicated. The Renilla luciferase plasmid was used as an internal control. *, P 0.05; **, P 0.01; ***, P 0.001.
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the transgene and more efficiently repressed Klf2 expression, we
used TMi2 for the subsequent analysis. In GFP- and HDAC4-
expressing cells, paxillinmarking FA is localized at the cell periph-
ery, with distinct punctate staining (Fig. 1D). In contrast, in
HDAC4/TM cells, a prominent diffuse staining of paxillin is evi-
dent, thus confirming the profound changes of actin cytoskeleton
and of FA.
To quantify the differences in adhesion/spreading elicited by
HDAC4/TM, we analyzed the behavior of the three cell lines when
plated onto BSA or fibronectin. Figure 1E demonstrates that
HDAC4/TM cells evidence a restricted spreading under both con-
ditions. Defects in cells spreading could be responsible for the
reduced size observed in Fig. 1A/D.
HDAC4 can influence cell motility (9). Since we have ob-
served an insightful rearrangement of actin cytoskeleton in
HDAC4/TM cells, we compared the random cell motility of the
different cell lines by performing a time-lapsemicroscopy anal-
ysis. Figure 1F shows that HDAC4/WT-expressing cells in-
crease motility to 0.78 m/min (standard error of the mean
[SEM] 
 0.026; n 
 141) compared to GFP-expressing cells
FIG 5 Regulation of the MEF2-dependent transcription by the PI3K/Akt pathway. (A) IMR90-E1A cells were transfected with the 3MEF2-Luc (1 g),
the internal control pRL-CMV (20 ng), pcDNA3.1-HA-MEF2C (1 g), and 300 ng of pEGFP expressing HDAC4. Cells were treated or not for 24 h with
LY. (B) IMR90-E1A cells were transfected as in panel A, together with the indicated HDAC4 mutants. Cells were treated or not for 24 h with LY. (C)
IMR90-E1A cells were transfected with the 3MEF2-Luc (1g), the internal control pRL-CMV (20 ng), pcDNA3.1-HA-MEF2C (1g), and 1g of pUSE
vectors expressing Myr-Akt or its catalytically inactive point mutant K179M. (D) IMR90-E1A cells transfected with siRNAs against HDAC4, HDAC5, and
HDAC9 or with the same amount of a control siRNA were cotransfected after 12 h with 3MEF2-Luc (1 g), the internal control pRL-CMV (20 ng), and
eventually pcDNA3.1-HA-MEF2C (1 g), as indicated. After 12 h, the cells were split into two plates and treated or not for 24 h with LY. (E) qRT-PCR
analysis was performed to quantify the mRNA levels of HDAC4, HDAC5, and HDAC9 in IMR90-E1A cells, cotransfected with the indicated siRNAs.
GAPDH was used as a control gene. *, P  0.05; **, P  0.01; ***, P  0.001.
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(0.56 m/min; SEM 
 0.02; n 
 136). This increase is signifi-
cantly more pronounced in cells expressing HDAC4/TM (1.15
m/min; SEM 
 0.04; n 
 171).
To confirm that the observed changeswere elicited byHDAC4/
TM, we silenced its expression using a human specific siRNA. The
efficiency of silencing was proved by immunoblotting and by aug-
mented Klf2 expression (Fig. 1G). The downregulation of
HDAC4/TM led to a reversion to the morphological changes de-
FIG 6 The PI3K/Akt pathway influencesMEF2 protein stability. (A)HDAC4was immunoprecipitated fromNIH3T3 cells treated or not for 18 hwith LY. TheHDAC
activity was measured 15 min after the addition of the developer. (B) Confocal pictures of IMR90-E1A cells transfected with pcDNA3.1-HA-MEF2C (1 g) and
pEGFPN1-HDAC4 (300ng) and treatedornotwithLY for 24h. Immunofluorescence analysiswas performed to visualizeHDAC4andMEF2C subcellular localization.
Scale bar, 50 m. (C) Quantification of endogenous HDAC4 subcellular localization in IMR90-E1A cells after the treatment with LY or DMSO for 24 h. For each
experiment, at least 200cellswere counted(n
3). (D) IMR90-E1Acellswere transfectedwithpcDNA3.1-HA-MEF2C(1g), and300ngofpEGFPexpressingHDAC4,
as indicated. After 12 h, cells were harvested, split into two plates and treated with the PI3K inhibitor LY. After 24 h, cellular lysates were generated and subjected to
immunoblot analysis using the anti-GFP and the anti-HA antibodies. Nucleoporin (p62) was used as loading control. (E) IMR90-E1A cells were transfected with
pcDNA3.1-HA-MEF2C(1g), and1gof pUSEvectors expressingMyr-Akt or its catalytically inactive pointmutantK179M.After 24h, cellular lysateswere generated
and subjected to immunoblot analysis with the anti-Akt and the anti-HA antibodies.Nucleoporin (p62)was used as loading control. (F) Immunoblot analysis ofMEF2
familymembers in IMR90-E1AandNIH3T3cells treatedwithLYand theproteasome inhibitorMG132as indicated. p120wasused as loading control. (G) IMR90-E1A
cellswere cotransfectedwithHA-ubiquitin andMEF2C-GFPorGFP.After 24h, the cellswere treatedornot for 12hwithLY, followedby12hwithMG132.GFP fusions
were immunoprecipitatedwith an antibody toGFPand subjected to immunoblottingwith an antiubiquitin antibody.After being stripped, the filterwas probedwith an
anti-GFP antibody. Inputs have been included. (H) Immunoblot analysis of MEF2C and MEF2D levels in NIH 3T3 cells expressing the catalytically active PI3K
(PI3KCA) treatedwithMG132 as indicated.Cellular lysateswere generated and subjected to immunoblot analysiswith the specific antibodies. TheAktphosphorylation
levels were also probed. p120was used as a loading control. (I)mRNA expression levels of selectedMEF2-HDAC4 target genes and Gapdh, as a control, weremeasured
using qRT-PCR in NIH 3T3 cells expressing PI3KCA or Puro. Samples were normalized to HPRT, GAPDH, and -actin. *, P 0.05; **, P 0.01; ***, P 0.001.
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scribed above. The cells increase spreading, rebuild stress fibers,
and reorganize FA (Fig. 1H).
HDAC4/TM induces cell transformation and tumorigenesis.
The altered morphology and the increased motility of cells ex-
pressing HDAC4/TM are reminiscent of a transformed pheno-
type. Moreover, the two cell lines expressing the TM allele have a
proliferative potential greater than cells expressing GFP or
HDAC4/WT, overcoming the contact inhibition, similarly to
HRasV12 transformed cells (Fig. 2A). To assess whether TM-ex-
pressing cells acquire parameters of transformation, we investi-
gated their ability to form colonies in soft agar (Fig. 2B and C).
Cells expressing HDAC4/TM but not GFP or HDAC4/WT devel-
oped large colonies in soft agar, similarly to HRasV12-expressing
cells. In summary, HDAC4/TM dismisses contact-dependent in-
hibition and confers anchorage-independent growth. Finally,
HDAC4/TM-engineered NIH 3T3 cells but not GFP or
HDAC4/WT cells generated tumors when subcutaneously in-
jected into athymic nude mice (Fig. 2D).
The oncogenic properties of the HDAC4/TM allele were con-
firmed also in BALB/c 3T3 cells, ruling out the possibility that the
observed phenotypes were context dependent (Fig. 2E to G). As
expected, HDAC4/WT was largely cytoplasmic, whereas the TM
mutant accumulated in the nucleus (data not shown). HDAC4/
TM-expressing but not HDAC/WT- or GFP-expressing BALB/c
3T3 cells were able to grow in soft agar (Fig. 2F). When BALB/c
3T3 cells expressing HDAC4/TM were subcutaneously injected
into nude mice, they efficiently generated tumors (Fig. 2G).
To understand whether HDAC4 shares with other class IIa
members this prooncogenic activity, we generated NIH 3T3 cells
expressing HDAC7/WT or its nucleus-localized version (S/A),
which is defective in all four serine binding sites for 14-3-3 pro-
teins (32). Similar to HDAC4/TM, HDAC7-S/A was mostly nu-
clear (Fig. 2H) and, although expressed to a lower extent com-
pared to the cytosolic HDAC7/WT (Fig. 2I), it exerted a stronger
repression on Klf2 expression (Fig. 2J). HDAC7-S/A cells mim-
icked the morphological changes observed in HDAC4/TM-ex-
pressing cells (data not shown). Moreover, similar to HDAC4/
TM, HDAC7-S/A conferred the NIH 3T3 transformed phenotype
and anchorage-independent growth capability (Fig. 2K). Overall,
our findings suggest that nucleus-resident class IIa HDACs can
elicit tumorigenic conversion of immortalized mouse fibroblasts.
Identification of genes under the influence of HDAC4. To
identify keymediators of class II HDAC oncogenic properties, the
transcriptional expression profiles of HDAC4/TM and HDAC4/
GFPwere compared. To further corroborate our results, microar-
ray analysis was also performed when HDAC4 expression was
silenced in TM cells. In this manner, we identified 47 genes whose
expression is both repressed in HDAC4/TM cells, compared to
GFP cells, and induced in HDAC4/TM cells after HDAC4 silenc-
ing (Fig. 3A).
We next examined the publicly available databases Gene On-
tology (www.geneontology.com) and Panther (www.pantherdb
.org) to assess the representation of different biological functions
among genes repressed by HDAC4/TM (Fig. 3B). The top-rank-
ing GO biological functions were proliferation (18%) and differ-
entiation/development/morphogenesis (13%). Interestingly, the
third category was the regulation of transcription/DNA binding,
and the top GO subcellular component is the nucleus (22%) (Fig.
3C). These evidences indicate that HDAC4 profoundly repro-
grams the expression profile and thus the cell fate. Not surpris-
ingly, several transcription factor genes (Nr4a1,Nr4a2, Klf2, Klf3,
Klf4, Bhlhe41, Pbx3, and Foxf1a) can be found among the 47 genes
repressed by HDAC4.
To gain insight into the signaling pathways deregulated by
HDAC4/TM, we used GSEA (30). We compared our DNA mi-
croarray data with gene sets from the 3,272 curated MSigDB data
sets. From this analysis we found that the phosphatidylinositol
3-kinase (PI3K)/Akt/mTOR signature is among the most en-
riched (data not shown). To confirm this result, we used as data
sets 91 DNAmicroarray experiments available onGEO, including
different models of transformation in murine fibroblasts and our
gene list as a gene set. The signature of HDAC4 significantly over-
laps genes repressed by the PI3K/Akt/mTOR pathway (Fig. 3D to
G) through PTEN ablation (33) (normalized enrichment score
[NES] 
 1.46, P 0.005) or TSC2 inhibition (34) (NES 
 1.61,
P  0.05). Furthermore, the HDAC4 signature is negatively en-
riched for gene expression profiles elicited by the inhibition of the
PI3K/Akt/mTORpathway, using the PI3K inhibitor LY (35) (NES

1.8485, P 0.005), or induced PTEN expression in Pten/
MEFs (33) (NES
1.5228, P 0.05).
Several genes repressed byHDAC4 areMEF2 targets and are
negatively regulated by the PI3K/Akt pathway. To validate the
microarray studies, we performed qRT-PCR analysis on a panel of
11 genes of the 47 described above, among which we included
some MEF2 targets (Klf2, Klf4, Edn1, and Nr4a1) and others not
previously associated with MEF2 (RhoB, Nr4a2, Trib1, Anxa8,
Irs1, Fgf7, and Errfi1). Gapdh was used as control. Furthermore,
GFP and HDAC4/TM cells were also treated with the PI3K inhib-
itor LY for 12 and 24 h to validate the GSEA. Except for Fgf7,
Errfi1, and Edn1, the expression of all HDAC4 targets was upregu-
FIG 7 MEF2 transcriptional activation can revert the oncogenic phenotype. (A) Immunoblot analysis ofMEF2-VP16-ER levels inNIH 3T3 cells expressing GFP
or HDAC4-TM/GFP or control vector (Hygro-Puro). MEF2-VP16-ER-dependent transcription was induced by treating cells with 4-OHT for 24 h. Cellular
lysates were generated and subjected to immunoblot analysis with anti-VP16 or anti-GFP antibodies. p62 (nucleoporin) was used as loading control. (B)
Confocal pictures showing MEF2-ER-VP16 nuclear accumulation after the induction with 4-OHT in NIH 3T3 HDAC4/TM cells (Hygro) stably expressing
MEF2-VP16-ER (Puro). Immunofluorescence analyses to visualize MEF2-VP16-ER subcellular localization were performed with an anti-VP16 antibody. Scale
bar, 50 m. (C) Confocal pictures of HDAC4/TM cells expressing MEF2-ER-VP16 chimera or its mutant defective in DNA binding MEF2DBD-ER-VP16
grown in the presence of 4-OHT. Immunofluorescence analysis was performed to visualize HDAC4 and paxillin subcellular localizations. AF546-phalloidin was
used to decorate F-actin. Scale bar, 50m. (D)mRNA expression levels of selectedMEF2-HDAC4 target genes andGapdh, as a control, were measured by using
qRT-PCR in HDAC4/TM cells expressing MEF2-ER-VP16 or the mutant MEF2DBD-ER-VP16. (E) HDAC4/TM cells were grown in DMEM supplemented
with 10%FBS. The day after seeding, 4-OHTwas added. (F)Quantitative results of colony formation in soft agar ofNIH3T3 cells expressingGFPorHDAC4/TM
and the twoMEF2 forms. The day after seeding, 4-OHTwas added to culturemedium. (G) Immunoblot analysis ofMEF2-VP16-ER andMEF2DBD-VP16-ER
levels in NIH 3T3 cells expressing PI3KCA or the control vector (Puro). MEF2-dependent transcription was induced by treating cells with 4-OHT for 24 h.
Cellular lysates were generated and subjected to immunoblot analysis with anti-VP16 or the indicated antibodies to monitor PI3K activation. p120 was used as
a loading control. (H) Quantitative results of colony formation in soft agar of NIH 3T3 cells expressing Puro or PI3KCA and the twoMEF2 forms. The day after
seeding, 4-OHT was added to the culture medium. *, P 0.05; **, P 0.01; ***, P 0.001.
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lated after inhibition of the PI3K signaling. Interestingly, addition
of the PI3K inhibitor reduces but did not abrogate the repressive
activity of HDAC4 on these genes (Fig. 4A).
In order to clarify which genes of the panel are MEF2 targets,
we generated NIH 3T3 cells expressing MEF2DN, a dominant-
negative version ofMEF2C (36) fused toGFP.MEF2DN-GFPwas
expressed at a lower level compared to HDAC4-GFP and less ef-
ficiently repressed MEF2-dependent transcription (data not
shown). Except for Errfi1, all of the selected HDAC4 target genes
were also downregulated after the expression of MEF2DN
(Fig. 4B). To further attest the identified genes as MEF2 targets,
we performed chromatin immunoprecipitation experiments in
MEF2C-GFP-overexpressing cells. We selected a set of genes
whose expression was influenced by MEF2DN, namely, Irs1,
RhoB, Klf4, Anxa8, and Klf2. All of the selected genes are signifi-
cantly enriched for MEF2 binding in the proximal promoter (Fig.
4C). Interestingly, several MEF2 targets identified by our study
(Irs1, RhoB, Klf2, Nr4a1, Nr4a2, Fgf7, and Trib1) have recently
been proposed as MEF2 targets in a lymphoblastic cell line by the
ENCODE project (37).
Since RhoB showed the highest enrichment in the ChIP exper-
iments, we decided to further prove its relationshipswithMEF2by
cloning its proximal promoter. The MEF2 consensus sequence
embedded in the RhoB proximal promoter is highlighted in Fig.
4D. Its coexpression, together with MEF2C, dramatically aug-
mented the luciferase activity, used as a reporter gene (Fig. 4F).
The PI3K/Akt pathway represses MEF2 transcriptional ac-
tivity. The GSEA and the effect of the PI3K inhibitor LY suggest
that the PI3K/Akt pathway could be involved in the regulation of
genes, which are also under the influence of MEF2/HDAC4 axis.
To further prove this relationship, we evaluated the ability of LY to
directly influence MEF2-dependent transcription. Human fibro-
blasts expressing the E1A oncogene were used for these studies
because of their high transfection efficiency. Treatment with LY
increased MEF2C-dependent transcription but modestly affected
the HDAC4 repressive influence (Fig. 5A). Similar results were
obtained in NIH 3T3 cells (data not shown). Afterward, we ex-
plored the susceptibility of a set of HDAC4 variants to LY treat-
ment. All of the different mutants show a behavior similar to that
of the WT, being able to suppress MEF2C-dependent transcrip-
tion also in the presence of the inhibitor (Fig. 5B). The only ex-
ception was the HDAC4 mutant lacking the amino terminus,
which is defective for MEF2 binding and thus for repressive activ-
ity (8).
The repressive effect of PI3K/Akt signaling pathway onMEF2-
dependent transcription was corroborated in IMR90-E1A cells
expressing a constitutive active (A) version (Myr-Akt) of Akt (Fig.
5C). IN contrast, a dominant-negative (I) form of Akt (K179M)
increased the MEF2C-dependent transcriptional activity (Fig.
5C). Similarly to the effect of LY, the repressive influence of
HDAC4 was only weakly affected by the coexpression of the Akt
variants.
HDAC4 and PI3K/Akt could exert their repressive influence
on MEF2-depedent transcription as components of the same
pathway or as independent arms of different signaling pathways.
To answer this question, we evaluated whether the depletion of
HDAC4 and LY showed additive effects on MEF2-dependent
transcription. Because of compensatory mechanisms and redun-
dant functions among class IIa HDACs (24), HDAC4, HDAC5,
and HDAC9 were simultaneously silenced. Together with the
three siRNAs, the MEF2-Luc reporter was cotransfected. Subse-
quently, the cells were incubated or not with LY. As a further
control, in an additional set of experiments, we ectopically ex-
pressed MEF2C.
Transcription from the MEF2 promoter was upregulated
2-fold after PI3K inhibition (Fig. 5D). Silencing of class IIa
HDAC4/5/9 increased transcription by4-fold. Downregulation
of class IIa HDACs in the presence of LY dramatically augmented
MEF2-dependent transcription (20-fold). When the experiment
was repeated in the presence of ectopic MEF2C, the trend was
similar. Silencing of class IIa HDACs and inhibition of the PI3K
pathway demonstrated additive effects onMEF2-dependent tran-
scription. Figure 5E shows the siRNA efficiency, as measured by
qRT-PCR.
The PI3K/Akt pathway influences MEF2 protein stability.
Although we have provided data that the PI3K/Akt pathway can
influence MEF2 transcriptional activity, the mechanism involved
remains obscure. In order to gain insight into the mechanisms
exerted by PI3K/Akt signaling onMEF2s, we analyzed whether LY
could influence the deacetylase activity associated with HDAC4
(Fig. 6A) or HDAC4 and MEF2C colocalization (Fig. 6B and C).
All of the analyzed parameters were unaffected by LY.
We next compared the levels of MEF2C when expressed in the
presence or absence of LY. We also coexpressed HDAC4 to eval-
uate its effect on MEF2C under these conditions. Immunoblot
analysis confirmed that HDAC4 influences the electrophoretic
mobility of MEF2C (Fig. 6D) (38). Importantly, LY augmented
MEF2C protein levels independently fromHDAC4. Similarly, the
coexpression of the inactive mutant of Akt sustained MEF2 ex-
pression, whereas the active form reduced its level (Fig. 6E).
To confirm that the PI3K/Akt can impact MEF2 stability, we
treated IMR90-E1A andNIH 3T3 cells with LY, in the presence or
not of the proteasome inhibitor MG132. Extracts were generated,
and the protein levels of MEF2C and MEF2D compared. LY and
MG132 can augment the levels of the twoMEF2 isoforms, and the
effect is not addictive (Fig. 6F). These data suggest that the PI3K/
Akt pathway impinges onMEF2 by controlling its turnover via the
ubiquitin-proteasome system. To prove this hypothesis, we eval-
uatedMEF2Cpolyubiquitination in the presence of LY. Coimmu-
noprecipitation studies in E1A cells, coexpressing MEF2C-GFP
and HA-ubiquitin, demonstrated that the PI3K/Akt pathway is
required for the polyubiquitination of MEF2C (Fig. 6G).
To further strengthen the relationships between MEF2 tran-
scription, protein degradation, and the PI3K/Akt pathway, we
generated NIH 3T3 cells expressing catalytic active PI3K. The lev-
els of bothMEF2C andMEF2D are reduced in cells expressing the
PI3KCA compared to control cells, and treatment with the pro-
teasome inhibitor rescued the levels of both MEF2 isoforms (Fig.
6H). In agreement with this observation, the expression levels of
several MEF2 targets (Klf2, End1, Irs1, and RhoB) were reduced in
cells expressing constitutive active PI3K (Fig. 6I).
ActivationofMEF2 reverses theoncogenic properties of cells
expressing HDAC4/TM and PI3K/CA. In addition to MEF2,
HDAC4 can influence other transcription factors and, of the iden-
tified 47 genes, some are not MEF2 targets. To understand
whether the oncogenic phenotype of cells expressing HDAC4 de-
pends on the repression of theMEF2 genetic program, we decided
to reactivate MEF2-dependent transcription in HDAC4-trans-
formed cells. We took advantage from aMEF2-VP16-ER chimera
in which the ligand-binding domain of the estrogen receptor (ER)
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is fused to the C terminus of the constitutively active MEF2-VP16
fusion protein (39).We also used as a control theMEF2-VP16-ER
lacking theDNA-binding domain (DBD aa58-86). Immunoblot
analysis of the different transgenes expressed in HDAC4/TM or
GFP cells is shown in Fig. 7A. We also monitored the subcellular
localization of MEF2-VP16-ER in HDAC4/TM cells to verify its
nuclear accumulation after 4-OHT treatment (Fig. 7B). Induction
of MEF2-VP16 in HDAC4/TM transformed cells reversed the
morphological alterations and promoted stress fiber formation
and focal adhesion assembling. In contrast, induction of
MEF2DBD-VP16 was ineffective (Fig. 7C).
Induction of MEF2-VP16 but not of its deletion version
(DBD) elicited the upregulation of MEF2 target genes also in
cells expressing HDAC4/TM (Fig. 7D). The reactivation of the
MEF2 program was sufficient to dramatically limit the prolifera-
tive potential of cells expressing HDAC4/TM to a level similar to
GFP-expressing cells (Fig. 7E). Finally, growth in soft agar of
HDAC4/TM-expressing cells was suppressed as well upon induc-
tion of MEF2-VP16 expression (Fig. 7F).
To corroborate the key role of MEF2 in counteracting trans-
formation, we introduced the MEF2-VP16-ER chimera or its
DNA-binding deletion version in PI3KCA-trasformed cells (Fig.
7G). Also in this case, the induction of MEF2-VP16 but not of its
deleted version (DBD) suppressed the ability of the transformed
cells to grow in soft agar (Fig. 7H). These results indicate that
MEF2 is an important target of the HDAC4 and PI3K transform-
ing activity and suggest that the repression of the MEF2 genetic
program is sufficient to confer oncogenic properties to NIH 3T3
cells.
HDAC4/TM defective in MEF2 binding loses its transform-
ing activity. To show that the repression of MEF2 transcription is
a key step for HDAC4 transforming activity, we constructed a
nuclear mutant of HDAC4 unable to complex MEF2. The MEF2
binding region, which comprises aa 166 to 184, was deleted from
HDAC4/TM to produce HDAC4/TMMEF2 (Fig. 8A). NIH 3T3
cells expressing HDAC4/TM and HDAC4/TMMEF2 were next
generated. The 166-184 mutant shows a clear nuclear localization
(Fig. 8B) and is expressed at levels similar to theHDAC4/TM (Fig.
8C). The repressive activity ofHDAC4/TMonKlf2 expressionwas
abrogated after the removal of aa 166 to 184 (Fig. 8D). A coimmu-
noprecipitation study confirmed that the binding to MEF2D was
impaired in the HDAC4/TMMEF2 mutant (Fig. 8E). Having
characterized the properties of this new mutant, we next investi-
gated its transforming ability. Figure 8F testifies that cells express-
ingHDAC4/TMMEF2 are unable to grow in soft agar in contrast
FIG 8 HDAC4/TM defective in MEF2 binding loses its transforming activity.
(A) Scheme of HDAC4/TM highlighting the deacetylase domain and the re-
gion involved inMEF2 binding. The deletionmutant generated for the present
study is also illustrated. (B) Confocal pictures of NIH 3T3 cells expressing
HDAC4/TM-GFP or its deleted version for MEF2 binding. Scale bar, 50 m.
(C) Immunoblot analysis of HDAC4/TM and HDAC4/TM/MEF2 levels in
NIH 3T3 cells. Immunoblot analysis was performedwith anti-GFP antibodies.
p62 (nucleoporin) was used as a loading control. (D) qRT-PCR analysis was
performed to quantify mRNAs levels of the HDAC4 target gene, Klf2. Gapdh
was used as a control gene.KLF2mRNA levels were relative to GFP-expressing
cells. (E) Cellular lysates from NIH 3T3 cells expressing HDAC4/TM and
HDAC4/TM/MEF2 were immunoprecipitated with an anti-GFP antibody.
Immunoblots were performed with anti-MEF2D and anti-GFP antibodies.
NRS, normal rabbit serum. (F)Quantitative results of colony formation in soft
agar of NIH 3T3 cells expressing the indicated transgenes. ***, P 0.001.
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to HDAC4/TM cells. In conclusion, these results further support
the idea that the repression of MEF2 transcription is essential for
HDAC4 transforming activity.
A signature of 25MEF2 target genes repressed by HDAC4 in
NIH 3T3 cells is significantly repressed in human in STS. Data
collected thus far suggest that dysfunctions of the MEF2-HDAC4
axis could play a role in tumorigenesis. As a first step for under-
standing our discovery in the context of human tumors, we de-
cided to explore whether the expression of 25 genes (see Fig. S1A
and B in the supplemental material), containing MEF2-binding
sites in the proximal promoters and whose expression was re-
pressed by HDAC4, is also repressed in human cancers. The tran-
scriptomes of 14 tumor types coming from 40 DNA microarray
GEO data sets were interrogated with this signature. This analysis
allowed us to discover that the MEF2 signature was significantly
repressed in soft tissue sarcoma (STS), gastric cancer, lymphoblas-
tic leukemia, and metastatic melanoma (Fig. 9A). In particular,
STSs turned out to be the tumors scoring the strongest repression
of these 25 genes. The downregulation of this MEF2 signature in
STSs was also confirmed by means of GSEA. The MEF2 signature
resulted significantly enriched in normal tissues compared to tu-
mors, and its repression parallels the progression of tumor malig-
nancy (Fig. 9B).
To further portray the association between STSs and theMEF2
signature, we applied a statistical analysis to determine the corre-
lation values, in terms of expression levels, between the 25 MEF2
targets and genes influencing their expression, including MEF2s,
class IIa HDACs, and PTEN, using two data sets (40, 41). Among
the MEF2 family members, MEF2C shows the highest expression
in STSs. As expected, theMEF2C levels correlate with the levels of
the 25MEF2 target genes (
 0.35; P 0.05). This result implies
that althoughMEF2 downregulation can contribute to the repres-
sion of MEF2 target gene in STSs, additional mechanisms also
exists. In both studies, PTEN was generally repressed, and its re-
pression correlatedwell with the levels of the 25MEF2 target genes
(Fig. 9C).
In STSs HDAC4 evidenced a heterogeneous pattern of expres-
sion (see Fig. S1C in the supplemental material and also Fig. 9D).
With the exclusion of the liposarcomas from the Gibault study
(Fig. 9C), we failed to observe a significant inverse correlation
betweenMEF2 target genes andHDAC4 expression. Interestingly,
when STSs were clustered into two groups based on the level of
PTEN expression: negative (0.5) or residual (0.5),
HDAC4 levels negatively correlated with theMEF2 signature only
in tumors displaying residual PTEN expression (Fig. 9D). The
expression of other class IIa members did not correlate with the
repression of the 25 MEF2 target genes (data not shown).
Immunohistochemical analysis of a series of 26 human pri-
mary leiomyosarcomas revealed a diffuse/pan, although weak re-
activity for anti-HDAC4 antibody in 12 cases (Fig. 9E2) and an
intense diffuse signal in 5 cases, with prominent nuclear accumu-
lation in 2 cases (Fig. 9E3). Immunohistochemical data are sum-
marized in Fig. S2 in the supplemental material. This result is in
line with our in silico predictions, evoking a contribution of
HDAC4 to the repression of MEF2 transcription only in a sub-
group of STSs.
MEF2 negatively impacts on the proliferation of human sar-
coma cells.Having discovered a correlation between MEF2 tran-
scriptional activity and STSs, we examined the contribution of
MEF2 to the tumorigenic phenotype of a panel of human leiomy-
osarcoma cell lines (LMS) (42).We initially verifiedwhether, sim-
ilarly to NIH 3T3 cells, MEF2D and MEF2C levels are under the
control of the PI3K/Akt pathway. Experiments with LY and
MG123, alone or in combination, indicated that in LMS cells the
PI3K/Akt pathway also controls MEF2C andMEF2D protein sta-
bility via the proteasome (Fig. 10A). Next, we engineered LMS
cells with the MEF2-VP16-ER chimera for inducible MEF2-de-
pendent transcription. The induction of MEF2 was sufficient to
reduce the proliferation (Fig. 10B), as well as the anchorage-inde-
pendent growth, of LMS cell lines (Fig. 10C). Overall, these results
support the hypothesis of MEF2 as a tumor suppressor in STSs.
Pharmacological cotargeting of the PI3K/Akt pathway and
of the MEF2-HDAC axis in sarcoma cells. To additionally prove
the independent and synergistic action of HDAC4 and of the
PI3K/Akt pathway onMEF2s and to evaluate the therapeutic per-
spective of our discovery, we used LY in conjunction with BML-
210, a recently defined inhibitor of the interaction between class
IIa HDACs and MEF2s (17).
BML-210 discharges the binding between HDAC4 and MEF2D
(Fig. 11A) and MEF2 transcriptional activity is augmented in the
presence of BML-210 (Fig. 11B). Moreover, both BML-210 and
LY inhibit the proliferation of LMS cell lines and, most impor-
tantly, the combination of the two drugs shows additive effects in
terms of the suppression of proliferation (Fig. 11C), which stems
from a delayed cell cycle progression, as shown in Fig. 11D.More-
over, the transcription of the MEF2 target genes KLF2, NR4A1,
and RHOBwas in general augmented in LMS cells when grown in
the presence of both drugs compared to single treatments (Fig.
11E).
DISCUSSION
This study provides unprecedented and compelling evidence of
the tumorigenic potential of the MEF2-HDAC axis. Murine
fibroblasts engineered to express nuclear active HDAC4 gain a
transformed phenotype, including elongated morphology, loss of
contact inhibition, anchorage-independent growth, and tumori-
genicity in a xenograft assay. Cell transformation as elicited by
HDAC4 is accompanied by the repression of a limited number of
genes, including several transcription factors. The selective influ-
ence of HDAC4 on the transcription of important regulatory
nodes can explain the dramatic shift in the proliferative attitude of
the cells.
FIG 9 Expression of theMEF2 target genes in human tumors. (A) Box plots depicted in light-bluemark tumors where theMEF2 signature is significantly below
zero and with at least the 50% of the values below an arbitrary threshold of 0.5. Significance was calculated by using the Poisson test (Holm-Bonferroni
correction, P 0.05). (B) GSEA on STSs, using the MEF2 signature as a gene set. (C) Expression level correlations between the MEF2 signature and HDAC4 or
PTEN in three different types of STSs. Statistically significant correlations are indicated in green, whereas statistically significant inverse correlations are indicated
in red. (D) Expression level correlations betweenMEF2 signature andHDAC4 in different types of STS subdivided into two subclasses according to the expression
of PTEN. Log2(PTEN) of 0.5 was selected as the cutoff to identify the two populations. Statistically significant inverse correlations are shown in red. (E)
Immunohistochemical analysis of HDAC4 expression in leiomyosarcoma. HDAC4 showed absent E1 (few positive inflammatory cells are present), low
pan/cytoplasmic expression E2, or increased expression and nuclear localization E3.
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Although MEF2s are important partners of HDAC4, the liter-
ature provide a long list of other proteins able to complex with
HDAC4 (18). Hence, whether the dysregulation of the MEF2-
HDAC4 axis is accountable for the oncogenic behavior cannot be
automatically evoked. Our results indicate that repression of the
MEF2 genetic program is crucial for the HDAC4 transforming
action. First, most (70%) of the genes repressed by HDAC4 are
putative MEF2 targets. Second, the restoration of the MEF2-de-
pendent transcription in cells expressing nuclear HDAC4 reverts
the transformed phenotype. Third, loss of MEF2 binding abro-
gates the transforming capability of nuclear active HDAC4.
The oncogenic potential appears to be shared among class IIa
members. An HDAC7 mutant defective for 14-3-3 binding was
also able to transformNIH 3T3 cells. Of note, amutation in serine
155 of HDAC7, a binding site for 14-3-3 proteins, has been re-
cently described in non-Hodgkin lymphoma (43). Although over-
expression of the WT forms of HDAC4 and HDAC7 was insuffi-
cient for a robust transformation, we cannot exclude that in vivo
an increase of class IIa HDACs levels might have an impact on
MEF2 and on tumor development (11, 24, 44).
Genes identified as targets of the MEF2-HDAC4 axis can also
be repressed by PI3K/Akt signaling. HDAC4 and the PI3K/Akt
pathway repressMEF2 transcription through independent routes.
Although HDAC4 binds MEF2s and possibly generates a re-
pressed state on chromatin (1), the PI3K/Akt signaling promotes
polyubiquitination and proteasome-mediated degradation of
MEF2s. Previous studies have reported that, in the context ofmus-
cle differentiation, the PI3K/Akt pathway could enhance MEF2
transcriptional activity (45, 46). However, the mechanism en-
gaged by Akt is debated, and there are evidences contrasting with
the idea of Akt as an activator ofMEF2 (47).Most importantly, the
positive influence of the PI3K/Akt pathway on MEF2s was not
confirmed in cancer cells (45). Analogous to our findings, the
phosphorylation-dependent degradation ofMEF2C has been pre-
viously reported (48).
The subset ofMEF2 targets repressed byHDAC4 turned out to
be significantly repressed in certain tumors, particularly in STSs,
which share with NIH 3T3 the mesenchymal origin, highlighting
the relevance of the cell context in HDAC4/MEF2-mediated phe-
notypes (19). Importantly, reactivation of MEF2 transcription in
PI3K-transformed cells and also in human sarcoma cell lines was
sufficient to reduce proliferation and to impact on anchorage-
independent growth.
In STSs, repression of the MEF2 targets mainly correlates with
the downregulation of PTEN, the negative regulator of the PI3K/
Akt pathway. Intriguingly, in tumors that retain partial PTEN
expression, MEF2 targets are still repressed. In these cases, repres-
sion inversely correlates with HDAC4 levels. This suggests that
PTEN loss and HDAC4 overexpression could represent two
alternative mechanisms for suppressing the MEF2 genetic pro-
gram in STS.
FIG 10 Regulation and functions of MEF2s in human sarcoma cells. (A)
Immunoblot analysis of MEF2C and MEF2D levels in human sarcoma cell
lines treated or not with LY. Cellular lysates were generated and subjected to
immunoblot analysis with the indicated antibodies. (B) Human sarcoma cells
expressing MEF2-VP16-ER or MEF2DBD-VP16-ER were grown in DMEM
supplemented with 10% FBS. The day after seeding, 4-OHT was added to
culture medium. (C) Quantitative results of colony formation in soft agar of
human sarcoma cells expressing MEF2-VP16-ER or MEF2DBD-VP16-ER.
The day after seeding, 4-OHT was added to culture medium. ***, P 0.001.
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FIG 11 Pharmacological targeting ofMEF2-HDAC axis and PI3K/Akt pathway. (A) Cellular lysates from IMR90-E1A cells treated or not for 36 hwith BML-210
were immunoprecipitated with an anti-HDAC4 antibody. Immunoblots were performed with the anti-MEF2D and anti-HDAC4 antibodies. (B) IMR90-E1A
cells were transfected as described in Fig. 5A. After 12 h, the cells were treated or not with BML-210 for 36 h. (C)Human sarcoma cells were seeded in 96-well and
treated for 48 h with LY and/or BML-210. The proliferative rate was scored by using a resazurin assay. (D) Doubling time (DB) of human sarcoma cells (5 104)
treated as in panel C. The DBwas calculated according to the following formula: DB
 (t2 t1)·[log2/log(q2/q1)], where t2 is time 2, t1 is time 1, q1 is the number
cells at t1, and q2 is the number of cells at t2. (E) mRNA expression levels of selected MEF2-HDAC4 target genes and Gapdh, as a control, were measured using
qRT-PCR in human sarcoma cells treated for 36 h as in panel C. (F) Model representing the two different actions of PI3K/Akt signaling and of HDAC4 on
MEF2-dependent transcription. *, P 0.05; **, P 0.01; ***, P 0.001.
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The independent action of HDAC4 and of PI3K/Akt onMEF2
was confirmed also by the use of selective inhibitors. Blocking the
PI3K/Akt pathway and impeding the interaction between MEF2
and class IIa HDACs produced additive effects on the transcrip-
tion of MEF2 target genes and much strongly suppressed prolif-
eration in sarcoma cell lines. This observation highlights the im-
portance of targeting both pathways for the development of more
efficient therapies for the treatment of STS.
In conclusion, our work suggests a model (Fig. 11F) wherein
MEF2 is a converging hub for the transformation promoted by
different oncogenic pathways. In this context, MEF2s behave as
tumor suppressors, which suggests that the restoration of MEF2
activity could be exploited as a novel therapeutic avenue.
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